

TITLE OF THE INVENTION:

Recombinantly-Modified Adeno-Associated Virus (rAAV) Having Improved Packaging Efficiency

FIELD OF THE INVENTION:

[0001] The present invention is directed to recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency, pharmaceutical compositions comprising such rAAV, and methods for their production and use. The present invention is particularly directed to recombinantly-modified adeno-associated virus (rAAV) that have been further modified to comprise Cis-Elements, including replication origins, promoters and enhancers, that are capable of regulating the replication of an rAAV genome and that improve rAAV replication. Preferably, such Cis-Elements are provided within domains of the rAAV that precede and/or follow the 5' and/or 3' inverted terminal repeated sequences (ITR) of an rAAV. The invention particularly concerns the presence and the use of polynucleotide Cis-Elements that comprise actual or potential G-Quadruplex Sequences, polynucleotide Cis-Elements that comprise DNA sequences from wild-type AAV (wt AAV) and polynucleotide Cis-Elements that comprise DNA sequences from other viral genomes or from the human genome.

REFERENCE TO SEQUENCE LISTING

[0002] This application includes one or more Sequence Listings pursuant to 37 C.F.R. 1.821 et seq., which are disclosed in computer-readable media (file name: 2650-0003US_ST25.txt, created on July 15, 2019, and having a size of 63,309 bytes), which file is herein incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION:

I. Adeno-Associated Virus (AAV)

[0003] Adeno-Associated Virus (AAV) is a small, naturally-occurring, non-pathogenic virus belonging to the *Dependovirus* genus of the *Parvoviridae* (Balakrishnan, B. *et al.* (2014) “*Basic Biology of Adeno-Associated Virus (AAV)*”

Vectors Used in Gene Therapy,” Curr. Gene Ther. 14(2):86-100; Zinn, E. *et al.* (2014) “Adeno-Associated Virus: Fit To Serve,” Curr. Opin. Virol. 0:90-97). Despite not causing disease, AAV is known to be able to infect humans and other primates and is prevalent in human populations (Johnson, F.B. *et al.* (1972) “Immunological Reactivity of Antisera Prepared Against the Sodium Dodecyl Sulfate-Treated Structural Polypeptides of Adenovirus-Associated Virus,” J. Virol. 9(6):1017-1026). AAV infect a broad range of different cell types (*e.g.*, cells of the central nervous system, heart, kidney, liver, lung, pancreas, retinal pigment epithelium or photoreceptor cells, or skeletal muscle cells). Twelve serotypes of the virus (*e.g.*, AAV2, AAV5, AAV6, *etc.*), exhibiting different tissue infection capabilities (“**tropisms**”), have been identified (Colella, P. *et al.* (2018) “Emerging Issues in AAV-Mediated In Vivo Gene Therapy,” Molec. Ther. Meth. Clin. Develop. 8:87-104; Hocquemiller, M. *et al.* (2016) “Adeno-Associated Virus-Based Gene Therapy for CNS Diseases,” Hum. Gene Ther. 27(7):478-496; Lisowski, L. *et al.* (2015) “Adeno-Associated Virus Serotypes For Gene Therapeutics,” 24:59-67).

[0004] AAV is a single-stranded DNA virus that is composed of approximately 4,700 nucleotides. The viral genome may be described as having a 5' half and a 3' half which together comprise the genes that encode the virus' proteins (**Figure 1**). The 5' half of the AAV genome comprises the AAV *rep* gene, which, through the use of multiple reading frames, staggered initiating promoters (**p5**, **p19** and **p40**) and alternate splicing, encodes four non-structural **Rep** proteins (**Rep40**, **Rep52**, **Rep68** and **Rep78**) that are required for viral transcription control and replication and for the packaging of viral genomes into the viral capsule (Lackner, D.F. *et al.* (2002) “Studies of the Mechanism of Transactivation of the Adeno-Associated Virus p19 Promoter by Rep Protein,” J. Virol. 76(16):8225-8235). The 3' half the AAV genome comprises the AAV capsid gene (*cap*), which encodes three **capsid** proteins (**VP**): **VP1**, **VP2** and **VP3**. The three capsid proteins are translated from a single mRNA transcript that is controlled by a single promoter (p40 in case of AAV2). The 3' half of the AAV genome also comprises the **AAP** gene, which encodes the AAV assembly-activating protein (**AAP**). Sixty VP monomers (comprising approximately 5 copies of VP1, 5 copies of VP2, and 50 copies of VP3) self-assemble around the AAV genome to form the icosahedral protein shell (**capsid**) of the mature viral particle (Büning, H. *et al.* (2019) “Capsid Modifications

for Targeting and Improving the Efficacy of AAV Vectors,” Mol. Ther. Meth. Clin. Devel. 12:P248-P265; Van Vliet K.M. *et al.* (2008) *The Role of the Adeno-Associated Virus Capsid in Gene Transfer*. In: DRUG DELIVERY SYSTEMS, Jain, K.K. (eds.), Meth. Molec. Biol. 437:51-91). The AAV **AAP** protein is believed to be required for stabilizing and transporting newly produced VP proteins from the cytoplasm into the cell nucleus. The 3' half of the AAV genome also comprises the AAV **X** gene, which is believed to encode a protein that supports genome replication (Colella, P. *et al.* (2018) “Emerging Issues in AAV-Mediated In Vivo Gene Therapy,” Molec. Ther. Meth. Clin. Develop. 8:87-104; Büning, H. *et al.* (2019) “Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors,” Mol. Ther. Meth. Clin. Devel. 12:P248-P265; Cao, M. *et al.* (2014) “The X Gene Of Adeno-Associated Virus 2 (AAV2) Is Involved In Viral DNA Replication,” PLoS ONE 9, e104596:1-10).

[0005] The above-described AAV gene-coding sequences are flanked by two AAV-specific palindromic inverted terminal repeated sequences (**ITR**) of 145 nucleotides (Balakrishnan, B. *et al.* (2014) “Basic Biology of Adeno-Associated Virus (AAV) Vectors Used in Gene Therapy,” Curr. Gene Ther. 14(2):86-100; Colella, P. *et al.* (2018) “Emerging Issues in AAV-Mediated In Vivo Gene Therapy,” Molec. Ther. Meth. Clin. Develop. 8:87-104).

[0006] AAV is an inherently defective virus, lacking the capacity to perform at least two critical functions: the ability to initiate the synthesis of viral-specific products and the ability to assemble such products to form the icosahedral protein shell (**capsid**) of the mature infectious viral particle. It thus requires a co-infecting “helper” virus, such as adenovirus (**Ad**), herpes simplex virus (**HSV**), cytomegalovirus (**CMV**), vaccinia virus or human papillomavirus to provide the viral-associated (**VA**) RNA that is not encoded by the genes of the AAV genome. Such VA RNA is not translated, but plays a role in regulating the translation of other viral genes. Similarly, the AAV genome does not include genes that encode the viral proteins E1a, E1b, E2a, and E4 of Ad; thus, these proteins must also be provided by a co-infecting “helper” virus. The E1a protein greatly stimulate viral gene transcription during the productive infection. The E1b protein block apoptosis in adenovirus-infected cells, and thus allow productive infection to proceed. The E2a protein plays a role in the elongation phase of viral strand displacement replication by unwinding the template and enhancing the initiation of

transcription. The E4 protein has been shown to affect transgene persistence, vector toxicity and immunogenicity (see, Grieger, J.C. *et al.* (2012) “*Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications*,” *Meth. Enzymol.* 507:229-254; Dyson, N. *et al.* (1992) “*Adenovirus E1A Targets Key Regulators Of Cell Proliferation*,” *Canc. Surv.* 12:161-195; Jones N.C. (1990) “*Transformation By The Human Adenoviruses*,” *Semin. Cancer Biol.* 1(6):425-435; Ben-Israel, H. *et al.* (2002) “*Adenovirus and Cell Cycle Control*,” *Front. Biosci.* 7:d1369-d1395; Hoebe, R.C. *et al.* (2013) “*Adenovirus DNA Replication*,” *Cold Spring Harb. Perspect. Biol.* 5:a013003 (pages 1-11); Berk, A.J. (2013) “*Adenoviridae: The Viruses And Their Replication*, In: *FIELDS VIROLOGY*, 6th Edition (Knipe, D.M. *et al.*, Eds.), Vol. 2., Lippincott Williams & Wilkins, Philadelphia, pages 1704-1731; Weitzman, M.D. (2005) “*Functions Of The Adenovirus E4 Proteins And Their Impact On Viral Vectors*,” *Front. Biosci.* 10:1106-1117).

[0007] AAV viruses infect both dividing and non-dividing cells, and persist as circular episomal molecules or can be integrated into the DNA of a host cell at specific chromosomal loci (**Adeno-Associated Virus Integration Sites** or **AAVS**) (Duan, D. (2016) “*Systemic Delivery Of Adeno-Associated Viral Vectors*,” *Curr. Opin. Virol.* 21:16-25; Grieger, J.C. *et al.* (2012) “*Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications*,” *Meth. Enzymol.* 507:229-254). AAV remains latent in such infected cells unless a helper virus is present to provide the functions needed for AAV replication and maturation.

II. rAAV and Their Use in Gene Therapy

[0008] In light of AAV's properties, recombinantly-modified versions of AAV (**rAAV**) have found substantial utility as vectors for gene therapy (see, Naso, M.F. *et al.* (2017) “*Adeno-Associated Virus (AAV) as a Vector for Gene Therapy*,” *BioDrugs* 31:317-334; Berns, K. I. *et al.* (2017) “*AAV: An Overview of Unanswered Questions*,” *Human Gene Ther.* 28(4):308-313; Berry, G.E. *et al.* (2016) “*Cellular Transduction Mechanisms Of Adeno-Associated Viral Vectors*,” *Curr. Opin. Virol.* 21:54-60; Blessing, D. *et al.* (2016) “*Adeno-Associated Virus And Lentivirus Vectors: A Refined Toolkit For The Central Nervous System*,” 21:61-66; Santiago-Ortiz, J.L. (2016) “*Adeno-Associated Virus (AAV) Vectors in Cancer Gene Therapy*,” *J. Control Release*

240:287-301; Salganik, M. *et al.* (2015) “Adeno-Associated Virus As A Mammalian DNA Vector,” *Microbiol. Spectr.* 3(4):1-32; Hocquemiller, M. *et al.* (2016) “Adeno-Associated Virus-Based Gene Therapy for CNS Diseases,” *Hum. Gene Ther.* 27(7):478-496; Lykken, E.A. *et al.* (2018) “Recent Progress And Considerations For AAV Gene Therapies Targeting The Central Nervous System,” *J. Neurodevel. Dis.* 10:16:1-10; Büning, H. *et al.* (2019) “Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors,” *Mol. Ther. Meth. Clin. Devel.* 12:P248-P265; During, M.J. *et al.* (1998) “In Vivo Expression Of Therapeutic Human Genes For Dopamine Production In The Caudates Of MPTP-Treated Monkeys Using An AAV Vector,” *Gene Ther.* 5:820-827; Grieger, J.C. *et al.* (2012) “Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications,” *Meth. Enzymol.* 507:229-254; Kotterman, M.A. *et al.* (2014) “Engineering Adeno-Associated Viruses For Clinical Gene Therapy,” *Nat. Rev. Genet.* 15(7):445-451; Kwon, I. *et al.* (2007) “Designer Gene Delivery Vectors: Molecular Engineering and Evolution of Adeno-Associated Viral Vectors for Enhanced Gene Transfer,” *Pharm. Res.* 25(3):489-499).

[0009] rAAV are typically produced using circular plasmids (“**rAAV plasmid vector**”). The AAV *rep* and *cap* genes are typically deleted from such constructs and replaced with a promoter, a β -globin intron, a cloning site into which a therapeutic gene of choice (**transgene**) has been inserted, and a poly-adenylation (“**polyA**”) site. The inverted terminal repeated sequences (ITR) of the rAAV are, however, retained, so that the **transgene expression cassette** of the rAAV plasmid vector is flanked by AAV ITR sequences (Colella, P. *et al.* (2018) “Emerging Issues in AAV-Mediated In Vivo Gene Therapy,” *Molec. Ther. Meth. Clin. Develop.* 8:87-104; Büning, H. *et al.* (2019) “Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors,” *Mol. Ther. Meth. Clin. Devel.* 12:P248-P265). Thus, in the 5' to 3' direction, the rAAV comprises a 5' ITR, the transgene expression cassette of the rAAV, and a 3' ITR.

[0010] rAAV have been used to deliver a transgene to patients suffering from any of a multitude of genetic diseases (*e.g.*, hereditary lipoprotein lipase deficiency (**LPLD**), Leber's congenital amaurosis (**LCA**), aromatic L-amino acid decarboxylase deficiency (**AADC**), choroideremia and hemophilia), and have utility in new clinical modalities, such as in interfering RNA (**RNAi**) therapy and gene-modifying strategies such as **Crispr/Cas9** (US Patents No. 8,697,359, 10,000,772, 10,113,167, 10,227,611; Lino,

C.A. *et al.* (2018) “*Delivering CRISPR: A Review Of The Challenges And Approaches*,” Drug Deliv. 25(1):1234-1237; Ferreira, V. *et al.* (2014) “*Immune Responses To AAV-Vectors, The Glybera Example From Bench To Bedside*” Front. Immunol. 5(82):1-15), Büning, H. *et al.* (2019) “*Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors*,” Mol. Ther. Meth. Clin. Devel. 12:P248-P265; Rastall, D.P.W. (2017) “*Current and Future Treatments for Lysosomal Storage Disorders*,” Curr. Treat Options Neurol. 19(12):45; Kay, M. *et al.* (2017) “*Future Of rAAV Gene Therapy: Platform For RNAi, Gene Editing And Beyond*,” Human Gene Ther. 28:361-372); Berns, K. I. *et al.* (2017) “*AAV: An Overview of Unanswered Questions*,” Human Gene Ther. 28(4):308-313). More than 150 clinical trials involving rAAV have been instituted (Büning, H. *et al.* (2019) “*Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors*,” Mol. Ther. Meth. Clin. Devel. 12:P248-P265; Clément, N. *et al.* (2016) “*Manufacturing Of Recombinant Adeno-Associated Viral Vectors For Clinical Trials*,” Meth. Clin. Develop. 3:16002:1-7). The most commonly used AAV serotype for such recombinantly-modified AAV is **AAV2**, which is capable of infecting cells of the central nervous system, kidney, retinal pigment epithelium and photoreceptor cells. AAV serotype is **AAV9**, which infects muscle cells, also has been widely used (Duan, D. (2016) “*Systemic Delivery Of Adeno-Associated Viral Vectors*,” Curr. Opin. Virol. 21:16-25). AAV serotypes are described in US Patents No. 10,301,650; 10,266,846; 10,265,417; 10,214,785; 10,214,566; 10,202,657; 10,046,016; 9,884,071; 9,856,539; 9,737,618; 9,677,089; 9,458,517; 9,457,103; 9,441,244; 9,193,956; 8,846,389; 8,507,267; 7,906,111; 7,479,554; 7,186,552; 7,105,345; 6,984,517; 6,962,815; and 6,733,757.

III. Methods of rAAV Production

[0011] rAAV containing a desired transgene expression cassette are typically produced by human cells (such as **HEK293**) grown in suspension. Since, as described above, rAAV are defective viruses, additional functions must be provided in order to replicate and package rAAV.

[0012] Typically, rAAV are produced by transiently transfecting cells with an rAAV plasmid vector and a second plasmid vector that comprises an AAV helper function-providing polynucleotide that provides the **Rep52** and **Rep78** genes that are required

for vector transcription control and replication, and for the packaging of viral genomes into the viral capsule (**Rep40** and **Rep68** are not required for rAAV production) and the *cap* genes that were excised from the AAV in order to produce the rAAV. The second plasmid vector may additionally comprise a non-AAV helper function-providing polynucleotide that encodes the viral transcription and translation factors (E1a, E1b, E2a, VA and E4) required for AAV proliferation, so as to comprise, in concert with the rAAV, a **double plasmid transfection system** (Grimm, D. *et al.* (1998) “*Novel Tools For Production And Purification Of Recombinant Adeno-Associated Virus Vectors*,” Hum. Gene Ther. 9:2745-2760; Penaud-Budloo, M. *et al.* (2018) “*Pharmacology of Recombinant Adeno-associated Virus Production*,” Molec. Ther. Meth. Clin. Develop. 8:166-180).

[0013] However, it has become increasingly common to clone the AAV helper function-providing polynucleotide (which provides the required *rep* and *cap* genes) into an “**AAV helper plasmid**,” and to clone the non-AAV helper function-providing polynucleotide (which provides the genes that encode the viral transcription and translation factors) on a different plasmid (*i.e.*, an “**Ad helper plasmid**”), so that such plasmids, in concert with an rAAV plasmid vector, comprise a **triple plasmid transfection system (Figure 2)**. Use of the triple plasmid transfection system has the advantage of permitting one to easily switch one *cap* gene for another, thereby facilitating changes in the rAAV’s serotype. The use of helper plasmids, rather than helper viruses, permits rAAV to be produced without additionally producing particles of the helper virus (François, A. *et al.* (2018) “*Accurate Titration of Infectious AAV Particles Requires Measurement of Biologically Active Vector Genomes and Suitable Controls*,” Molec. Ther. Meth. Clin. Develop. 10:223-236; Matsushita, T. *et al.* (1998) “*Adeno-Associated Virus Vectors Can Be Efficiently Produced Without Helper Virus*,” Gene Ther. 5:938-945).

[0014] The transient transfection of plasmid DNAs comprising the rAAV plasmid vector, the AAV *rep* and *cap* genes, and the trans-acting AAD helper genes into HEK293 cells by calcium phosphate coprecipitation has become the standard method to produce rAAV in the research laboratory (Grimm, D. *et al.* (1998) “*Novel Tools For Production And Purification Of Recombinant Adeno-Associated Virus Vectors*,” Hum. Gene Ther. 9:2745-2760). However, the use of such a calcium phosphate-mediated

transfection process with suspension-cultured transfected mammalian cells requires media exchanges, and is thus not considered ideal for the large-scale rAAV production that is required in order to produce therapeutic doses of rAAV (Lock, M. *et al.* (2010) “*Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale*,” Hum. Gene Ther. 21:1259-1271). For this reason, polyethylenimine (**PEI**), has been used as a transfection reagent and has been found to provide yields of virus that are similar to those obtained using calcium phosphate-mediated transfection (Durocher, Y. *et al.* (2007) “*Scalable Serum-Free Production Of Recombinant Adeno-Associated Virus Type 2 By Transfection Of 293 Suspension Cells*,” J. Virol. Meth. 144:32-40).

[0015] rAAV may alternatively be produced in insect cells (*e.g.*, sf9 cells) using baculoviral vectors (see, *e.g.*, US Patents No.: 9,879,282; 9,879,279; 8,945,918; 8,163,543; 7,271,002 and 6,723,551), or in HSV-infected baby hamster kidney (**BHK**) cells (*e.g.*, BHK21 (François, A. *et al.* (2018) “*Accurate Titration of Infectious AAV Particles Requires Measurement of Biologically Active Vector Genomes and Suitable Controls*,” Molec. Ther. Meth. Clin. Develop. 10:223-236). Methods of rAAV production are reviewed in Grieger, J.C. *et al.* (2012) “*Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications*,” Meth. Enzymol. 507:229-254, and in Penaud-Budloo, M. *et al.* (2018) “*Pharmacology of Recombinant Adeno-associated Virus Production*,” Molec. Ther. Meth. Clin. Develop. 8:166-180.

IV. Methods of rAAV Purification and Recovery


[0016] After production, rAAV are typically collected and purified by one or more overnight CsCl gradient centrifugations (Zolotukhin, S. *et al.* (1999) “*Recombinant Adeno-Associated Virus Purification Using Novel Methods Improves Infectious Titer And Yield*,” Gene Ther. 6:973-985), followed by desalting to form a purified rAAV production stock. Titers of 10^{12} - 10^{13} infectious rAAV capsids/mL are obtainable.

[0017] Because rAAV infection does not cause a cytopathic effect, plaque assays cannot be used to determine the infectious titer of an rAAV preparation. Infectious titer is thus typically measured as the median tissue culture infective dose (**TCID₅₀**). In this method, a HeLa-derived AAV2 *rep*- and *cap*-expressing cell line is grown in a 96-well plate and infected with replicate 10-fold serial dilutions of the rAAV preparation,

in the presence of adenovirus of serotype 5. After infection, vector genome replication is determined by quantitative PCR (qPCR) (Zen, Z. *et al.* (2004) “*Infectious Titer Assay For Adeno-Associated Virus Vectors With Sensitivity Sufficient To Detect Single Infectious Events*,” Hum. Gene Ther. 15:709-715). Alternatively, the infectious titer of an rAAV preparation can be measured using the infectious center assay (ICA). This assay uses HeLa *rep-cap* cells and Ad, but, after incubation, involves transferring the cells to a membrane. A labeled probe that is complementary to a portion of the employed transgene is used to detect infectious centers (representing individual infected cells) via hybridization. Although more widely used, the TCID₅₀ assay has been reported to lead to a higher background than the ICA and to overestimate vector infectivity relative to the ICA (François, A. *et al.* (2018) “*Accurate Titration of Infectious AAV Particles Requires Measurement of Biologically Active Vector Genomes and Suitable Controls*,” Molec. Ther. Meth. Clin. Develop. 10:223-236). Methods of producing and purifying rAAV are described *inter alia* in US Patents No. 10,294,452; 10,161,011; 10,017,746; 9,598,703; 7,625,570; 7,439,065; 7,419,817; 7,208,315; 6,995,006; 6,989,264; 6,846,665 and 6,841,357.

V. G-Quadruplex Sequences and Structures

[0018] DNA can form several secondary structures besides the classic double helix; one that has received much attention in recent years is the **G-Quadruplex Structure**. G-Quadruplex Structures are formed from the stacking of three planar “**G-tetrad**” (also known as “**guanine quartet**”) structures. Each G-tetrad is formed through Hoogsteen base pairing via hydrogen bond interactions involving four deoxyguanosine residues. The planar structure of the G-tetrad may be stabilized by cations (*e.g.*, Na⁺). In the G-tetrad structure shown below, the guanines are attached to their respective polynucleotide chain(s) via “**R**”.



G-Tetrad / Guanine Quartet

[0019] The stacking of G-tetrad structures to form a G-Quadruplex Structure is accomplished by the spontaneous interaction and/or looping of domains of one, two or four polynucleotide chains that together comprise a G-Quadruplex Sequence (**Figures 3A-3D**).

[0020] G-Quadruplex Structures are well known in the art (Bedrat, A. *et al.* (2016) “*Re-evaluation of G-Quadruplex propensity with G4Hunter*,” *Nucleic Acids Res.* 44(4):1746-1759; Harris, L.M. *et al.* (2015) “*G-Quadruplexes In Pathogens: A Common Route To Virulence Control?*” *PLoS Pathog.* 11(2):e1004562 (pages 1-15); Siddiqui-Jain, A. *et al.* (2002) “*Direct Evidence For A G-Quadruplex In A Promoter Region And Its Targeting With A Small Molecule To Repress c-MYC Transcription*,” *Proc. Natl. Acad. Sci. (U.S.A.)* 99:11593-11598; Wieland, M. *et al.* (2007) “*RNA Quadruplex-Based Modulation Of Gene Expression*,” *Chem. Biol.*, 14:757-763; Millevoi, S. *et al.* (2012) “*G-Quadruplexes In RNA Biology*,” *Wiley interdiscip. Rev. RNA* 3:495-507; Lopes, J. *et al.* (2011) “*G-Quadruplex-Induced Instability During Leading-Strand Replication*,” *EMBO J.* 30:4033-4046; Paeschke, K. *et al.* (2011) “*DNA Replication Through G-Quadruplex Motifs Is Promoted By The Saccharomyces Cerevisiae Pif1 DNA Helicase*,” *Cell* 145:678-691; Besnard, E. *et al.* (2012) “*Unraveling Cell Type-Specific And Reprogrammable Human Replication Origin Signatures Associated With G-Quadruplex Consensus Motifs*,” *Nat. Struct. Mol. Biol.*

19:837-844; and Valton, A.L. *et al.* (2014) “*G4 Motifs Affect Origin Positioning And Efficiency In Two Vertebrate Replicators*,” *EMBO J.* 33:732-746).

[0021] Sequences capable of forming G-Quadruplex Structures have been recently identified within the genome of a number of viruses, *e.g.*, HIV, HSV, EBV influenza, papillomavirus and cauliflower mosaic virus (Piekna-Przybylska, D. *et al.* (2014) “*U3 Region In The HIV-1 Genome Adopts A G-Quadruplex Structure In Its RNA And DNA Sequence*,” *Biochemistry* 53(16):2581-2593; Artusi, S. *et al.* (2015) “*The Herpes Simplex Virus-1 Genome Contains Multiple Clusters Of Repeated G-Quadruplex: Implications For The Antiviral Activity Of A G-Quadruplex Ligand*,” *Antivir. Res.* 118:123-131; Tlučková, K. *et al.* (2013) “*Human Papillomavirus G-Quadruplexes*,” *Biochemistry* 52(41):7207-7216; Métifiot, M. *et al.* (2014) “*G-Quadruplexes In Viruses: Function And Potential Therapeutic Applications*,” *Nucleic Acids Res.* 42(20):12352-12366).

[0022] Viral G-Quadruplex Structures have been proposed to function as steric blocks to DNA replication and transcription (Satkunanathan, S. *et al.* (2017) “*The Function Of DNA Binding Protein Nucleophosmin In AAV Replication*,” *Virol.* 510:46-54). For example, the presence of a G-Quadruplex Sequence in the wild-type Nuclease hypersensitive element III (NHE III₁) gene, a major regulator of c-MYC transcription, causes that gene to be expressed at a lower level than that of a mutated NHE III₁ gene (Siddiqui-Jain, A. *et al.* (2002) “*Direct Evidence For A G-Quadruplex In A Promoter Region And Its Targeting With A Small Molecule To Repress c-MYC Transcription*,” *Proc. Natl. Acad. Sci. (U.S.A.)* 99:11593-11598; Harris, L.M. *et al.* (2015) “*G-Quadruplexes In Pathogens: A Common Route To Virulence Control?*” *PLoS Pathog.* 11(2):e1004562 (pages 1-15).

[0023] It has been proposed that limitations in high titer AAV production may be due to AAV's dependence on helper viruses and on an insufficient understanding of factors, viral or cellular, that contribute to AAV replication (Satkunanathan, S. *et al.* (2017) “*The Function Of DNA Binding Protein Nucleophosmin In AAV Replication*,” *Virol.* 510:46-54). In this regard, investigations into the life cycle of AAV have revealed that AAV helper genes function to induce cellular factors that were either missing or inactivated in a normal cell cycle (Muzyczka, N. (1992) “*Use Of Adeno-Associated*

Virus As A General Transduction Vector For Mammalian Cells,” Curr. Top. Microbiol. Immunol. 158:97-129; Ni, T.H. *et al.* (1998) “*Cellular Proteins Required For Adeno-Associated Virus DNA Replication In The Absence Of Adenovirus Coinfection*,” J. Virol. 72(4):2777-2787). Additionally, cellular and viral DNA binding proteins have been found to play a vital role in AAV life cycle in unwinding AAV double-stranded DNA, nicking single-stranded DNA, facilitating single-stranded DNA association with nuclei and ultimately enhancing viral DNA production and protein expression (Weitzman, M.D. (2006) “*The Parvovirus Life Cycle: An Introduction To Molecular Interactions Important For Infection*,” In: Kerr, J.R. *et al.* (Eds.) PARVOVIRUSES, Hodder Arnold, London, UK; Satkunanathan, S. *et al.* (2017) “*The Function Of DNA Binding Protein Nucleophosmin In AAV Replication*,” Virol. 510:46-54).

[0024] For example, **Nucleophosmin (NPM1)** is a nucleolar protein that plays a role in many diverse functions, such as genome stability, DNA duplication and transcriptional regulation through its ability to bind to single-stranded nucleic acids. Nucleophosmin has been reported to enhance AAV infection by acting as a chaperone protein to mobilize AAV capsids into and out of the nucleolus (Nash, K. *et al.* (2009) “*Identification Of Cellular Proteins That Interact With The Adeno-Associated Virus Rep Protein*,” J. Virol. 83(1):454-469; Ni, T.H. *et al.* (1998) “*Cellular Proteins Required For Adeno-Associated Virus DNA Replication In The Absence Of Adenovirus Coinfection*,” J. Virol. 72(4):2777-2787; Nicolas, A. *et al.* (2012) “*Factors Influencing Helper-Independent Adeno-Associated Virus Replication*,” Virology 432(1):1-9). Nucleophosmin has, however, also been found to negatively regulate DNA replication by binding to G-Quadruplex Sequences (Gallo, A. *et al.* (2012) “*Structure of Nucleophosmin DNA-binding Domain and Analysis of Its Complex with a G-Quadruplex Sequence from the c-MYC Promoter*,” J. Biol. Chem. 287(32):26539-26548). The down-regulation of Nucleophosmin has been found to result in an increase in AAV2 and AAV8 vector production (Satkunanathan, S. *et al.* (2017) “*The Function Of DNA Binding Protein Nucleophosmin In AAV Replication*,” Virol. 510:46-54), and the destruction or elimination of G-Quadruplex Sequences has been found to unblock G-Quadruplex Structure-mediated inhibition of viral DNA replication of HIV and HSV (Harris, L.M. *et al.* (2015) “*G-Quadruplexes In Pathogens: A Common Route To Virulence Control?*” PLoS Pathog. 11(2):e1004562 (pages 1-15)). Thus, the presence

of G-Quadruplex Sequences has been reported to inhibit AAV vector production (Satkunanathan, S. *et al.* (2017) “*The Function Of DNA Binding Protein Nucleophosmin In AAV Replication*,” Virol. 510:46-54).

[0025] Despite all such prior advances, a need remains to develop methods capable of addressing problems that presently limit the applicability of rAAV to gene therapy (Grieger, J.C. *et al.* (2012) “*Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications*,” Meth. Enzymol. 507:229-254; Kotterman, M.A. *et al.* (2014) “*Engineering Adeno-Associated Viruses For Clinical Gene Therapy*,” Nat. Rev. Genet. 15(7):445-451; Kwon, I. *et al.* (2007) “*Designer Gene Delivery Vectors: Molecular Engineering and Evolution of Adeno-Associated Viral Vectors for Enhanced Gene Transfer*,” Pharm. Res. 25(3):489-499; Naso, M.F. *et al.* (2017) “*Adeno-Associated Virus (AAV) as a Vector for Gene Therapy*,” BioDrugs 31:317-334).

[0026] The present invention is directed to improved methods for increasing the efficiency of AAV and rAAV packaging through regulation of the replication of rAAV genomes.

SUMMARY OF THE INVENTION:

[0027] The present invention is directed to recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency, pharmaceutical compositions comprising such rAAV, and methods for their production and use. The present invention is particularly directed to recombinantly-modified adeno-associated virus (rAAV) that have been further modified to comprise Cis-Elements, including replication origins, promoters and enhancers, that are capable of regulating the replication of an rAAV genome and that improve rAAV replication. Preferably, such Cis-Elements are provided within domains of the rAAV that precede and/or follow the 5' and/or 3' inverted terminal repeated sequences (ITR) of an rAAV. The invention particularly concerns the presence and the use of polynucleotide Cis-Elements that comprise actual or potential G-Quadruplex Sequences, polynucleotide Cis-Elements that comprise DNA sequences from wild-type AAV (wt AAV) and polynucleotide Cis-Elements that comprise DNA sequences from other viral genomes or from the human genome.

[0028] In detail, the invention provides a recombinantly-modified adeno-associated virus (rAAV) that comprises a Cis-Element in one or more of its **P1**, **P2**, **P3** or **P4 Domains**, wherein:

- (1) the **P1 Domain** is 5' to a 5' ITR of the rAAV;
- (2) the **P2 Domain** is 3' to the 5' ITR of the rAAV and 5' to a transgene cassette of the rAAV;
- (3) the **P3 Domain** is 3' to the transgene cassette of the rAAV and 5' to a 3' ITR of the rAAV; and
- (4) the **P4 Domain** is 3' to the 3' ITR of the rAAV; and

wherein the presence of the Cis-Element causes rAAV-producing cells to produce the rAAV at a higher production titer than would be attained with such rAAV if lacking the Cis-Element.

[0029] The invention also provides a pharmaceutical composition that comprises:

- (A) a preparation of recombinantly-modified adeno-associated virus (rAAV) that comprise a Cis-Element in one or more of its **P1**, **P2**, **P3** or **P4 Domains**, wherein:
 - (1) the **P1 Domain** is 5' to a 5' ITR of the rAAV;
 - (2) the **P2 Domain** is 3' to the 5' ITR of the rAAV and 5' to a transgene cassette of the rAAV;
 - (3) the **P3 Domain** is 3' to the transgene cassette of the rAAV and 5' to a 3' ITR of the rAAV; and
 - (4) the **P4 Domain** is 3' to the 3' ITR of the rAAV; and
- (B) a pharmaceutically acceptable carrier.

[0030] The invention also provides a method for increasing the production titer of recombinantly-modified adeno-associated virus (rAAV), wherein the method comprises:

- (A) employing, as the rAAV for producing the production titer, an rAAV that has been modified to comprise an added Cis-Element in one or more of its **P1**, **P2**, **P3** or **P4 Domains**, wherein:
 - (1) the **P1 Domain** is 5' to a 5' ITR of the rAAV;
 - (2) the **P2 Domain** is 3' to the 5' ITR of the rAAV and 5' to a transgene cassette of the rAAV;

- (3) the **P3 Domain** is 3' to the transgene cassette of the rAAV and 5' to a 3' ITR of the rAAV; and
- (4) the **P4 Domain** is 3' to the 3' ITR of the rAAV; and
- (B) culturing cells that have been transfected with the employed rAAV, wherein the cells additionally contain an AAV helper function-providing polynucleotide and a non-AAV helper function-providing polynucleotide, and wherein the culturing is conducted in a culture medium under conditions sufficient to permit the production of rAAV; wherein the presence of the Cis-Element in the employed rAAV causes the cells to produce the rAAV at an increased production titer relative to that which would be attained if the employed rAAV had lacked the Cis-Element.

[0031] The invention also provides the embodiment of such recombinantly-modified adeno-associated virus (rAAV), pharmaceutical composition, or method, wherein the employed rAAV has been modified to comprise an added Cis-Element in its **P1 Domain**.

[0032] The invention also provides the embodiment of such recombinantly-modified adeno-associated viruses (rAAV), pharmaceutical compositions, or methods, wherein the employed rAAV has been modified to comprise an added Cis-Element in its **P2 Domain**.

[0033] The invention also provides the embodiment of such recombinantly-modified adeno-associated viruses (rAAV), pharmaceutical compositions, or methods, wherein the employed rAAV has been modified to comprise an added Cis-Element in its **P3 Domain**.

[0034] The invention also provides the embodiment of such recombinantly-modified adeno-associated viruses (rAAV), pharmaceutical compositions, or methods, wherein the employed rAAV has been modified to comprise an added Cis-Element in its **P4 Domain**.

[0035] The invention also provides the embodiment of such recombinantly-modified adeno-associated viruses (rAAV), pharmaceutical compositions, or methods, wherein

the employed rAAV has been modified to comprise an added Cis-Element in its **P1 Domain** and in one or more of its **P2, P3 or P4 Domain**.

[0036] The invention also provides the embodiment of such recombinantly-modified adeno-associated viruses (rAAV), pharmaceutical compositions, or methods, wherein the employed rAAV has been modified to comprise an added Cis-Element in its **P2 Domain** and in one or more of its **P3 or P4 Domain**.

[0037] The invention also provides the embodiment of such recombinantly-modified adeno-associated viruses (rAAV), pharmaceutical compositions, or methods, wherein the employed rAAV has been modified to comprise an added Cis-Element in its **P3 Domain** and in its **P4 Domain**.

[0038] The invention also provides the embodiment of such recombinantly-modified adeno-associated viruses (rAAV), pharmaceutical compositions, or methods, wherein the added Cis-Element forms a G-Quadruplex Structure in the employed rAAV.

[0039] The invention also provides the embodiment of such recombinantly-modified adeno-associated viruses (rAAV), pharmaceutical compositions, or methods, wherein an added Cis-Element is selected from the group consisting of:

- (1) a Potential G-Quadruplex Sequence of a wild type AAV genome or a Potential G-Quadruplex Sequence of a wild type AAV genome in a reversed orientation;
- (2) an Actual G-Quadruplex Sequence of a wild type AAV genome or an Actual G-Quadruplex Sequence of a wild type AAV genome in a reversed orientation;
- (3) a DNA sequence from wild-type AAV or a DNA sequence from wild-type AAV in a reversed orientation; and
- (4) a DNA sequence from another viral genome or a DNA sequence from another viral genome in a reversed orientation.

[0040] The invention also provides the embodiment of such recombinantly-modified adeno-associated viruses (rAAV), pharmaceutical compositions, or methods, wherein the transgene cassette encodes a protein, or comprises a transcribed nucleic acid, that is therapeutic for a genetic or heritable disease or condition.

[0041] The invention also provides the embodiment of such recombinantly-modified adeno-associated viruses (rAAV), pharmaceutical compositions, or methods, wherein the employed rAAV belongs to the rAAV1, rAAV2, rAAV5, rAAV6, rAAV7, rAAV8, rAAV9 or rAAV10 serotype, or to a hybrid of the serotypes.

[0042] The invention also provides the embodiment of such recombinantly-modified adeno-associated viruses (rAAV), pharmaceutical compositions, or methods, wherein the employed rAAV belongs to the rAAV2, rAAV5, or rAAV9 serotype, or to a hybrid of the serotypes.

[0043] The invention also provides the embodiment of such recombinantly-modified adeno-associated viruses (rAAV), pharmaceutical compositions, or methods, wherein the cells are human embryonic kidney cells, baby hamster kidney cells or sf9 insect cells.

[0044] The invention also provides the embodiment of such recombinantly-modified adeno-associated viruses (rAAV), pharmaceutical compositions, or methods, wherein the cells are HEK293 human embryonic kidney cells.

[0045] The invention also provides the embodiment of such recombinantly-modified adeno-associated viruses (rAAV), pharmaceutical compositions, or methods, wherein the cells are BHK21 baby hamster kidney cells.

[0046] The invention also provides such recombinantly-modified adeno-associated viruses (rAAV) and pharmaceutical compositions, wherein the transgene cassette encodes a protein, or comprises a transcribed nucleic acid, that is therapeutic for a genetic or heritable disease or condition, for use in the treatment of the genetic or heritable disease or condition.

BRIEF DESCRIPTION OF THE DRAWINGS:

[0047] **Figure 1** provides a schematic genetic map of the wild-type (**Wt**) AAV genome.

[0048] **Figure 2** provides a schematic of the structural domain of the wild-type AAV2 genome (**1**), a recombinant AAV (rAAV) (**2**), complementing “AAV helper plasmid”

(3) and an adenovirus helper plasmid (“Ad helper plasmid”) **(4)**. The wild-type (Wt) AAV2 **(1)** is composed of AAV-specific palindromic inverted terminal repeated sequences (**ITR**), a 5’ half containing genes that encode the **Rep** proteins and a 3’ half containing genes that encode the **Cap** proteins. The rAAV **(2)** is formed by replacing the **Rep**- and **Cap**-encoding genes of the wild-type (Wt) AAV2 **(1)** with a transgene cassette that comprises a promoter (**Pro**), the exogenous transgene of interest, and a polyadenylation site (**pA**). In order to produce the rAAV **(2)**, a complementing “AAV helper” plasmid vector **(3)** and an adenovirus helper plasmid vector (Ad helper plasmid) **(4)** are provided. The complementing AAV helper plasmid **(3)** provides **Rep** and **Cap** proteins. The Ad helper plasmid **(4)** provides adenovirus proteins E1a, E1b, E2a, VA and E4.

[0049] **Figures 3A-3D** show illustrative **G-Quadruplex Structures** formed by the stacking of multiple G-tetrads. **Figures 3A-3D** depict such G-tetrad as gray planar rectangles whose vertices are connected to the polynucleotide backbone. The G-Quadruplex Structures may be formed from a single polynucleotide chain (**Figures 3A-3B**), that spontaneously loops back upon itself, from two polynucleotide strands (**Figure 3C**) that loop back upon each other, or from four polynucleotide chains (**Figure 3D**) that loop back upon each other. The ability of such polynucleotide chains to form such G-tetrads and to form such loops depends upon their presence of **G-Quadruplex Sequences**; such one, two or four polypeptide chains may form loops in either an anti-parallel manner (*e.g.*, **Figure 3A**) or in a parallel manner (*e.g.*, **Figure 3B**) (see, Harris, L.M. *et al.* (2015) “*G-Quadruplexes In Pathogens: A Common Route To Virulence Control?*” PLoS Pathog. 11(2):e1004562 (pages 1-15).

[0050] **Figure 4** shows a map of the AAV helper plasmid vector **pAAV-RC2**.

[0051] **Figure 5** shows a map of the non-AAV helper plasmid vector **pHelper-Kan**.

[0052] **Figure 6** shows a map of the rAAV plasmid vector **pAV-CMV-EGFP**.

[0053] **Figure 7** shows a map of the rAAV plasmid vector **pAV-TBG-EGFP**.

[0054] **Figure 8** shows the overall structure and approach followed for the development of the exemplary rAAV constructs described herein (**ITR**: adeno-

associated virus (AAV)-specific palindromic inverted terminal repeated sequences; **Pro**: promoter. **Gene**: transgene; **PolyA**: polynucleotide comprising poly-deoxyadenosine sequence; **CisE**: polynucleotide comprising a Cis-Element).

[0055] **Figures 9A-9B** show the increase in rAAV production titers obtained by introducing a Cis-Element within the **P2 Domain** of the rAAV plasmid vector **pAV-TBG-EGFP**. **Figure 9A** shows the **P2 Domain** of the rAAV plasmid vector **pAV-TBG-EGFP**. **Figure 9B** shows the production titers of rAAV obtained using rAAV plasmid vectors containing any of Cis-Elements CisE1-CisE27 (**Table 1**), relative to that obtained using the parental rAAV plasmid vector, **pAV-TBG-EGFP**. The production titers of rAAV were obtained using the parental or derivative rAAV plasmids in a triple plasmid transfection system with a helper plasmid providing the AAV *rep* and *cap* functions and an Ad helper plasmid that provided the required adenoviral functions.

[0056] **Figures 10A-10B** show the increase in rAAV production titers obtained by introducing a Cis-Element within the **P1 Domain** of the rAAV plasmid vector **pAV-TBG-EGFP** (**Figure 10A**). **Figure 10B** shows the production titers of rAAV obtained using rAAV plasmid vectors containing any of Cis-Elements CisE1, CisE20, CisE21, CisE27, CisE28, CisE29, or CisE30 (**Table 1**), relative to that obtained using the parental rAAV plasmid vector, **pAV-TBG-EGFP**. The production titers of rAAV were obtained using the parental or derivative rAAV plasmid vectors in a triple plasmid transfection system with an AAV helper plasmid providing the AAV *rep* and *cap* functions and an Ad helper plasmid that provided the required adenoviral functions.

[0057] **Figures 11A-11B** show the increase in rAAV production titers obtained by introducing the same Cis-Element within the **P1 Domain** or **P2 Domain** of the rAAV plasmid vector **pAV-TBG-EGFP** (**Figure 11A**). **Figure 11B** shows the production titers of rAAV obtained using rAAV plasmids containing any of Cis-Elements CisE1, CisE20, or CisE21 (**Table 1**), relative to that obtained using the parental rAAV plasmid, **pAV-TBG-EGFP**. The production titers of rAAV were obtained using the parental or derivative rAAV plasmids in a triple plasmid transfection system with an AAV helper plasmid providing the AAV *rep* and *cap* functions and an Ad helper plasmid that provided the required adenoviral functions.

[0058] **Figures 12A-12B** show the effect of Cis-Element orientation on the ability of a Cis-Element, inserted within the **P1 Domain** the rAAV plasmid vector **pAV-TBG-EGFP**, to cause an increase in rAAV production titer (**Figure 12A**). **Figure 12B** shows the production titers of rAAV obtained using rAAV plasmid vectors containing Cis-Element CisE21 (**Table 1**) in the forward orientation (**SEQ ID NO:41**) (“CisE21-For-P1”) or in the reverse orientation (**SEQ ID NO:42**) (“CisE21-Rev-P1”), relative to that obtained using the parental rAAV plasmid vector, **pAV-TBG-EGFP**. The production titers of rAAV were obtained using the parental or derivative rAAV plasmids in a triple plasmid transfection system with an AAV helper plasmid providing the AAV *rep* and *cap* functions and an Ad helper plasmid that provided the required adenoviral functions.

[0059] **Figures 13A-13D** show the effect of Cis-Element orientation on the ability of a Cis-Element, inserted within both the **P1 Domain** the rAAV plasmid vector **pAV-TBG-EGFP** and the **P4 Domain** of such plasmid vector to cause an increase in rAAV production titer (**Figure 13A**). **Figure 13B** shows the production titers of rAAV obtained using rAAV plasmid vectors containing different Cis-Elements (Cis-Element CisE21, CisE22, CisE23, CisE24, CisE25, CisE26, CisE28, CisE29, CisE31, CisE32, CisE33, CisE34, or CisE35) within the **P1 Domain**, while maintaining the same Cis-Element (CisE30-Rev) within the **P4 Domain** of the rAAV plasmid vector. **Figure 13C** shows the production titers of rAAV obtained using rAAV plasmid vectors containing different Cis-Elements (Cis-Element CisE21, CisE22, CisE23, CisE24, CisE25, CisE27, CisE28, CisE32, CisE33, or CisE34) within its **P1 Domain** and Cis-Element CisE35-Rev within its **P4 Domain**. **Figure 13D** shows the production titers of rAAV obtained using rAAV plasmid vectors containing different Cis-Elements (Cis-Element CisE22-Rev, CisE27-Rev, CisE29-Rev, or CisE35-Rev) within the **P4 Domain**, while maintaining the same Cis-Element (CisE28) within the **P1 Domain** of the rAAV plasmid vector. The production titers of rAAV were obtained using the parental or derivative rAAV plasmids in a triple plasmid transfection system with an AAV helper plasmid providing the AAV *rep* and *cap* functions and an Ad helper plasmid that provided the required adenoviral functions.

DETAILED DESCRIPTION OF THE INVENTION:

I. The Methods of the Present Invention

[0060] The present invention is directed to recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency, pharmaceutical compositions comprising such rAAV, and methods for their production and use. The present invention is particularly directed to recombinantly-modified adeno-associated virus (rAAV) that have been further modified to comprise Cis-Elements, including replication origins, promoters and enhancers, that are capable of regulating the replication of an rAAV genome and that improve rAAV replication. Preferably, such Cis-Elements are provided within domains of the rAAV that precede and/or follow the 5' and/or 3' inverted terminal repeated sequences (ITR) of an rAAV. The invention particularly concerns the presence and the use of polynucleotide Cis-Elements that comprise actual or potential G-Quadruplex Sequences, polynucleotide Cis-Elements that comprise DNA sequences from wild-type AAV (wt AAV) and polynucleotide Cis-Elements that comprise DNA sequences from other viral genomes or from the human genome.

[0061] The present invention is based in part on the recognition that high levels of DNA replication increase both the amount of rAAV genomes particles and, consequently, the efficiency of rAAV packaging, and thus result in high production titers of rAAV stocks. Such desired high levels of DNA replication can be attained by modifying rAAV or rAAV plasmid vectors to contain additional polynucleotides that comprise replication origins, promoters, enhancers, *etc.* Because such polynucleotides act to increase the replication of rAAV vectors on which they are present, they are referred to herein as “**Cis-Elements**.” The invention encompasses recombinant AAV vectors and rAAV plasmid vectors that carry such Cis-Elements and their use in the production of novel stable cell lines capable of generating high titer rAAV preparations. The Cis-Elements of the present invention are preferably introduced into an rAAV plasmid vector. Such introduction is preferably accomplished using well-known methods of recombinant DNA technology.

[0062] As used herein, the term “**AAV**” is intended to denote adeno-associated virus, and may be used to refer to the virus itself or derivatives thereof. The term covers all

subtypes and both naturally occurring and recombinant forms. As used herein, the term “**rAAV**” is intended to denote a recombinantly-modified version of AAV that comprises a polynucleotide sequence not of AAV origin (*i.e.*, a polynucleotide heterologous to AAV). The rAAV may be single-stranded or double-stranded, and may be composed of deoxyribonucleotides or ribonucleotides.

[0063] As used herein, the term “**AAV helper functions**” denotes AAV proteins (*e.g.*, **Rep** and **Cap**) and/or polynucleotides of AAV that are required for the replication and packaging of an rAAV. Such AAV helper functions are provided by an “**AAV helper function-providing polynucleotide**,” which as such term is used herein is a virus, plasmid vector, a non-plasmid vector, or a polynucleotide that has been integrated into a cellular chromosome, that provides AAV helper functions. AAV helper plasmids that may be used in accordance with the present invention to provide **AAV helper functions**, such as pAAV-RC (Agilent; Addgene; Cell Biolabs), pAAV-RC2 (Cell Biolabs), *etc.*, are commercially available. Plasmid **pAAV-RC2 (SEQ ID NO:1; Figure 4)** is an AAV helper plasmid that may be used in accordance with the present invention to provide **AAV helper functions**.

Coding Strand of Plasmid pAAV-RC2 (SEQ ID NO:1):

```

cctgggcccc cctcgaggct gacgggtatcg ggggagctcg cagggtctcc
atthttgaagc gggaggthttg aacgcgcagc cgccatgccg gggthtttacg
agattgtgat taaggthccc agcgaccttg acgagcatct gcccggtatt
tctgacagct ttgtgaactg ggtggccgag aaggaatggg agttgccgcc
agattctgac atggatctga atctgattga gcaggcacc ctgaccgtgg
ccgagaagct gcagcgcgac ttctgacgg aatggcgccg tgtgagtaag
gccccggagg ctctthttctt tgtgcaattt gagaaggagg agagctactt
ccacatgcac gtgctcgtgg aaaccaccgg ggtgaaatcc atggthtttg
gacgtthtctt gactcagatt cgcgaaaaaac tgattcagag aatttaccgc
gggatcgagc cgactthtgc aaactgggtc gcggtcacia agaccagaaa
tgccgcccga ggcgggaaca aggtgggtga tgagtgtctac atccccatt
acttgctccc caaaaccag cctgagctcc agtgggcgtg gactaatatg
gaacagtatt taagcgctg thtgaatctc acggagcgta aacggttgg
ggcgagcat ctgacgcagc tgtcgagac gcaggagcag aacaaagaga
atcagaatcc caattctgat ggcgggtga tcagatcaa aacttcagcc
aggtacatgg agctggctcg gtggctcgtg gacaagggga ttacctcgga
gaagcagtg atccaggagg accaggcctc atacatctcc ttcaatgcgg
cctccaactc gcggtcccaa atcaaggctg ccttggaaca tgccgggaaag
attatgagcc tgactaaaac cgcctccgac tacctgggtg gccagcagcc
cgtggaggac atthtccagca atcggtthta taaaatttht gaactaaacg
ggtacgatcc ccaatatgcg gcttccgtct thtctgggatg ggccacgaaa
aagttcggca agaggaacac catctggctg thtgggcctg caactaccgg
gaagaccaac atcgcgagg ccatagccca cactgtgccc thtctacgggt
gcgtaaaactg gaccaatgag aactthtccct tcaacgactg tgtcgacaag

```

atggtgatct	ggtgggagga	ggggaagatg	accgccaagg	tcgtggagtc
ggccaaagcc	attctcggag	gaagcaaggt	gcgcgtggac	cagaaatgca
agtcctcggc	ccagatagac	ccgactcccg	tgatcgtcac	ctccaacacc
aacatgtgcg	ccgtgattga	cgggaactca	acgaccttcg	aacaccagca
gccgttgcaa	gaccggatgt	tcaaatttga	actcaccgcg	cgtctggatc
atgacttttg	gaaggtcacc	aagcaggaag	tcaaagactt	tttccggtgg
gcaaaggatc	acgtggttga	ggtggagcat	gaattctacg	tcaaaaaggg
tgagagccaag	aaaagaccgc	ccccagtgga	cgcagatata	agtgaagcca
aacgggtgcg	cgagtcagtt	gcgcagccat	cgacgtcaga	cgcggaagct
tcgatcaact	acgcagacag	gtaccaaaaac	aaatgttctc	gtcacgtggg
catgaatctg	atgctgtttc	cctgcagaca	atgcgagaga	atgaatcaga
attcaaatat	ctgcttcact	cacggacaga	aagactgttt	agagtgcctt
cccgtgtcag	aatctcaacc	cgttttctgtc	gtcaaaaagg	cgtatcagaa
actgtgctac	attcatcata	tcatgggaaa	ggtgccagac	gcttgactcg
cctgcgatct	ggtcaatgtg	gatttggatg	actgcatctt	tgaacaataa
atgatttaaa	tcaggtatgg	ctgccgatgg	ttatcttcca	gattggctcg
aggacactct	ctctgaagga	ataagacagt	ggtggaagct	caaacctggc
ccaccaccac	caaagccgcg	agagcggcat	aaggacgaca	gcaggggtct
tgtgcttcct	gggtacaagt	acctcggacc	cttcaacgga	ctcgacaagg
gagagccggt	caacgaggca	gacgccgcgg	ccctcgagca	cgacaaagcc
tacgaccggc	agctcgacag	cggagacaac	ccgtacctca	agtacaacca
cgccgacgcg	gagtttcagg	agcgccttaa	agaagatacg	tcttttgggg
gcaacctcgg	acgagcagtc	ttccaggcga	aaaagagggg	tcttgaacct
ctgggcctgg	ttgaggaacc	tgtaagacg	gctccgggaa	aaaagaggcc
ggtagagcac	tctcctgtgg	agccagactc	ctcctcggga	accggaaagg
cgggccagca	gcctgcaaga	aaaagattga	atthttggtca	gactggagac
gcagactcag	tacctgacct	ccagcctctc	ggacagccac	cagcagcccc
ctctggtctg	ggaactaata	cgatggctac	aggcagtggc	gcaccaatgg
cagacaataa	cgagggcgcc	gacggagtgg	gtaattcctc	gggaaattgg
cattgcgatt	ccacatggat	gggcgacaga	gtcatcacca	ccagcaccgc
aacctggggc	ctgcccacct	acaacaacca	cctctacaaa	caaattttcca
gccaatcagg	agcctcgaac	gacaatcact	acttttggtca	cagcaccctt
tggggggtatt	ttgacttcaa	cagattccac	tgccactttt	caccacgtga
ctggcaaaga	ctcatcaaca	acaactgggg	attccgacct	aagagactca
acttcaagct	ctttaacatt	caagtcaaag	aggtcacgca	gaatgacggg
acgacgacga	ttgccaataa	ccttaccagc	acggttcagg	tggttactga
ctcggagtac	cagctcccgt	acgtcctcgg	ctcggcgcac	caaggatgcc
tcccgccggt	cccagcagac	gtcttcatgg	tgccacagta	tggtaccttc
acctgaaca	acgggagtca	ggcagtagga	cgctcttcat	tttactgcct
ggagtacttt	ccttctcaga	tgctgcgtac	cggaaacaac	tttaccttca
gctacacttt	tgaggacgtt	cctttccaca	gcagctacgc	tcacagccag
agtctggacc	gtctcatgaa	tcctctcatc	gaccagtacc	tgtattactt
gagcagaaca	aacactccaa	gtggaaccac	cacgcagtca	aggcttcagt
tttctcaggc	cggagcgagt	gacattcggg	accagtctag	gaactggctt
cctggaccct	gttaccgcca	gcagcgagta	tcaaagacat	ctgcggataa
caacaacagt	gaatactcgt	ggactggagc	taccaagtac	cacctcaatg
gcagagactc	tctggtgaat	ccgggcccgc	ccatggcaag	ccacaaggac
gatgaagaaa	agttttttcc	tcagagcggg	gttctcatct	ttgggaagca
aggctcagag	aaaacaaatg	tgacatttga	aaaggtcatg	attacagacg
aagaggaaat	caggacaacc	aatcccgtgg	ctacggagca	gtatggttct

gtatctacca	acctccagag	aggcaacaga	caagcagcta	ccgcagatgt
caacacacaa	ggcgttcttc	caggcatggt	ctggcaggac	agagatgtgt
accttcaggg	gcccattctgg	gcaaagattc	cacacacgga	cggacattttt
cacccctctc	ccctcatggg	tggattcgga	cttaaacacc	ctcctccaca
gattctcatc	aagaacaccc	cggtagctgc	gaatccttcg	accaccttca
gtgcggcaaa	gtttgcttcc	ttcatcacac	agtactccac	gggacaggtc
agcgtggaga	tcgagtggga	gctgcagaag	gaaaacagca	aacgctggaa
tcccgaattt	cagtacactt	ccaactacaa	caagtctgtt	aatgtggact
ttactgtgga	cactaatggc	gtgtattcag	agcctcgccc	cattggcacc
agatacctga	ctcgtaattct	gtaattgctt	gttaatcaat	aaaccgttta
attcgtttca	gttgaacttt	ggtctctgcy	tatttctttc	ttatctagtt
tccatgctct	aggatccact	agtaacggcc	gccagtgtgc	tgggaattcgg
ctttgtagtt	aatgattaac	cgcctatgct	acttatctac	gtagccatgc
tctagaggtc	ctgtattaga	ggtcacgtga	gtgttttgcy	acattttgcy
acaccatgtg	gtcacgctgg	gtattttaagc	ccgagtgagc	acgcagggtc
tccattttga	agcgggaggt	ttgaacgcgc	agccgccaa	ccgaattctg
cagatatcca	aacactggcg	gccgctcgac	tagagcgggc	gccaccgcgg
tggagctcca	gcttttgctc	ccttttagtga	gggttaattg	cgcgcttggc
gtaatcatgg	tcatagctgt	ttcctgtgtg	aaattgttat	ccgctcacaa
ttccacacaa	catacgagcc	ggaagcataa	agtgtaaagc	ctgggggtgcc
taatgagtga	gctaactcac	attaattgcy	ttgcgctcac	tgcccgcttt
ccagtcggga	aacctgtcgt	gccagctgca	ttaatgaatc	ggccaacgcg
cggggagagg	cggtttgctg	attgggcgct	cttccgcttc	ctcgctcact
gactcgctgc	gctcggtcgt	tcggctgcgg	cgagcggtat	cagctcactc
aaaggcggtg	atacggttat	ccacagaatc	aggggataac	gcaggaaaga
acatgtgagc	aaaaggccag	caaaaggcca	ggaaccgtaa	aaaggccgcg
ttgctggcgt	ttttccatag	gctccgcccc	cctgacgagc	atcacaaaaa
tcgacgtcca	agtcagaggt	ggcgaaaccc	gacaggacta	taaagatacc
aggcgtttcc	ccctggaagc	tcctctgtgc	gctctcctgt	tccgaccttg
ccgcttaccc	gatacctgtc	cgcctttctc	ccttcgggaa	gcgtggcgct
ttctcatagc	tcacgctgta	ggtatctcag	ttcgggtgtg	gtcgcttcgct
ccaagctggg	ctgtgtgcac	gaaccccccg	ttcagcccca	ccgctgcgcc
ttatccggta	actatcgtct	tgagtccaac	ccggtaagac	acgacttatc
gccactggca	gcagccactg	gtaacaggat	tagcagagcg	aggtagttag
gcggtgctac	agagttcttg	aagtgggtgg	ctaactacgg	ctacactaga
agaacagtat	ttggtatctg	cgctctgctg	aagccagtta	ccttcggaaa
aagagttggg	agctcttgat	ccggcaaaaca	aaccaccgct	ggtagcgggtg
gtttttttgt	ttgcaagcag	cagattacgc	gcagaaaaaa	aggatctcaa
gaagatcctt	tgatcttttc	tacgggggtct	gacgctcagt	ggaacgaaaa
ctcacgttaa	gggatttttg	tcatagagatt	atcaaaaagg	atcttcacct
agatcctttt	aaattaaaaa	tgaagtttta	aatcaatcta	aagtatatat
gagtaaactt	ggtctgacag	ttaccaatgc	ttaatcagtg	aggcacctat
ctcagcgatc	tgtctatttc	gttcatccat	agttgcctga	ctccccgtcg
tgtagataac	tacgatacgg	gagggccttac	catctggccc	cagtgtgcga
atgataccgc	gagaccacgc	ctcaccggct	ccagatttat	cagcaataaa
ccagccagcc	ggaagggccg	agcgcagaag	tggtcctgca	actttatccg
cctccatcca	gtctattaat	tggtgcccgg	aagctagagt	aagtagttcg
ccagttaata	gtttgcgcaa	cggtgttgcc	attgctacag	gcacgtgggt
gtcacgctcg	tcgtttggta	tggcttcatt	cagctccggg	tcccaacgat
caaggcgagt	tacatgatcc	cccatgttgt	gcaaaaaagc	ggtagctcc

```

ttcggtcctc cgatcgttgt cagaagtaag ttggccgcag tgttatcact
catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa
gatgcttttc tgtgactggt gagtactcaa ccaagtcatt ctgagaatag
tgtatgcggc gaccgagttg ctcttgcccg gcgtcaatac gggataatac
cgcgccacat agcagaactt taaaagtgct catcattgga aaacgttctt
cggggcgaaa actctcaagg atcttaccgc tgttgagatc cagttcgaatg
taaccactc gtgcacccaa ctgatcttca gcatctttta ctttcaccag
cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaagggaa
taaggcgac acggaaatgt tgaatactca tactcttcct ttttcaatat
tattgaagca tttatcaggg ttattgtctc atgagcggat acatatttga
atgtatttag aaaaataaac aaataggggt tccgcgcaca tttcccgaa
aagtgccacc taaattgtaa gcgttaatat tttgttaaaa ttcgcgttaa
atTTTTgtta aatcagctca ttttttaacc aataggccga aatcggcaaa
atcccttata aatcaaaaaga atagaccgag atagggttga gtgttggtcc
agtttggaac aagagtccac tattaagaa cgtggactcc aacgtcaaag
ggcgaaaaac cgtctatcag ggcgatggcc cactacgtga accatcacc
taatcaagtt ttttggggtc gaggtgccgt aaagcactaa atcggaaacc
taaagggagc ccccgattta gagcttgacg gggaaagccg gcgaacgtgg
cgagaaagga agggaagaaa gcgaaaggag cgggcgctag ggcgctggca
agtgtagcgg tcacgctgcg cgtaaccacc acaccgccg cgcttaatgc
gccgctacag ggcgctccc attcgccatt caggctgcgc aactgttggg
aaggcgatc ggtgcgggcc tcttcgctat tacgccagct ggcgaaagg
ggatgtgctg caaggcgatt aagttgggta acgccagggt tttccagtc
acgacgttgt aaaacgacgg ccagtgcgcg cgcgtaatac gactcactat
agggcgaatt gggtg

```

[0064] In SEQ ID NO:1, residues 85-1950 of **pAAV-RC2** encode the **Rep** protein, **Rep78** (with residues 484-663 corresponding to the **P19** promoter, residues 1464-1643 corresponding to the **P40** promoter and residues 1668-1676 being a donor site); residues 1967-4174 encode the capsid protein, **VP1**; residues 1992-2016 encodes a portion of the **Rep68** protein; residues 4175-4256 encode a polyA sequence; residues 4610-4626 are *M13 Rev* sequences; residues 4634-4650 are *Lac* operator sequences; 4658-4688 are *Lac* promoter sequences; residues 4951-5675 correspond to pMB ori sequences, residues 5771-6631 encode an ampicillin resistance determinant; and residues 6632-6730 are *bla* promoter sequences (**Figure 4**).

[0065] As used herein, the term “**non-AAV helper functions**” denotes proteins of Ad, CMV, HSV or other non-AAD viruses (*e.g.*, E1a, E1b, E2a, VA and E4) and/or polynucleotides of Ad, CMV, HSV or other non-AAD viruses that are required for the replication and packaging of an rAAV. Such non-AAV helper functions are provided by a “**non-AAV helper function-providing polynucleotide**,” which as such term is used herein is a virus, plasmid vector, a non-plasmid vector, or a polynucleotide that

has been integrated into a cellular chromosome, that provides non-AAV helper functions. The vector, **pHelper** and derivatives thereof (commercially available from Cell Biolabs, Inc., Invitrogen and Stratagene) are suitable non-AAV helper function-providing polynucleotide (see, *e.g.*, Matsushita, T. *et al.* (1998) “*Adeno-Associated Virus Vectors Can Be Efficiently Produced Without Helper Virus*,” *Gene Ther.* 5:938-945; Sharma, A. *et al.* (2010) “*Transduction Efficiency Of AAV 2/6, 2/8 And 2/9 Vectors For Delivering Genes In Human Corneal Fibroblasts*,” *Brain Res. Bull.* 81(2-3):273-278). Plasmid **pHelper-Kan (SEQ ID NO:2; Figure 5)** is a **non-AAV helper function-providing polynucleotide** that may be used in accordance with the present invention to provide **non-AAV helper functions**.

Coding Strand of Plasmid pHelper-Kan (SEQ ID NO:2):

```

ggtacccaac tccatgctta acagtcccca ggtacagccc accctgcgtc
gcaaccagga acagctctac agcttcctgg agcgccactc gccctacttc
cgcagccaca gtgcgagat taggagcgcc acttcttttt gtcacttgaa
aaacatgtaa aaataatgta ctaggagaca ctttcaataa aggcaaatgt
ttttatttgt acactctcgg gtgattatct acccccacc cttgccgtct
gcgccgttta aaaatcaaag gggttctgcc gcgcctcgt atgcgccact
ggcagggaca cgttgcgata ctggtgttta gtgctccact taaactcagg
cacaaccatc cgcggcagct cggtgaagtt ttcactccac aggctgcga
ccatcaccaa cgcgtttagc aggtcgggcg ccgatatctt gaagtcgcag
ttggggcctc cgccctgcgc gcgcgagttg cgatacacag ggttgacga
ctggaacact atcagcgccg ggtggtgcac gctggccagc acgctcttgt
cggagatcag atccgcgtcc aggtcctccg cgttgctcag ggcgaacgga
gtcaactttg gtagctgcct tcccaaaaag ggtgcatgcc caggctttga
gttgactctg caccgtagt gcatcagaag gtgaccgtgc ccggtctggg
cgtaggata cagcgccctg atgaaagcct tgatctgctt aaaagccacc
tgagcctttg cgccttcaga gaagaacatg ccgcaagact tgccggaaaa
ctgattggcc ggacaggccg cgtcatgcac gcagcacctt gcgtcgtgt
tgagatctg caccacattt cggccccacc ggttcttcac gatcttgcc
ttgctagact gctccttcag cgcgcgctgc ccgttttcgc tcgtcacatc
catttcaatc acgtgctcct tatttatcat aatgctcccg tgtagacact
taagctcgcc ttcgatctca gcgcagcggg gcagccacaa cgcgcagccc
gtgggctcgt ggtgcttgta gggtacctct gcaaacgact gcaggtacgc
ctgcaggaat cgcccatca tcgtcacaaa ggtcttggtg ctggtgaagg
tcagctgcaa cccgcggtgc tcctcgttta gccaggtctt gcatacggcc
gccagagctt ccacttggtc aggcagtagc ttgaagtttg ctttagatc
gttatccacg tggtagctgt ccatcaacgc gcgcgcagcc tccatgccct
tctcccacgc agacacgata ggcaggctca gcgggtttat caccgtgctt
tcactttccg cttcactgga ctcttccttt tcctcttgcg tccgcatacc
ccgcgccact gggtcgtctt cattcagccg ccgcaccgtg cgcttacctc
ccttgccgtg cttgattagc accggtgggt tgctgaaacc caccatttgt
agcgccacat cttctctttc ttctcgtctg tccacgatca cctctgggga
tgccggggcg tcgggcttgg gagaggggag cttctttttc tttttggacg
caatggccaa atccgcgctc gaggtcgatg gccgcgggct ggggtgtgcg
ggcaccagcg catcttgtag cgagtcttct tcgtcctcgg actcgagacg

```

ccgcctcage	cgcttttttg	ggggcgcgcg	gggaggcggc	ggcgacggcg
acggggacga	cacgtcctcc	atgggttggtg	gacgtcgcg	cgcaccgcgt
ccgcgctcgg	gggttggttc	gcgctgctcc	tcttcccgac	tggccatttc
cttctcctat	aggcagaaaa	agatcatgga	gtcagtcgag	aaggaggaca
gcctaaccgc	cccctttgag	ttcgccacca	ccgcctccac	cgatgccgcc
aacgcgccta	ccaccttccc	cgtcgaggca	cccccgcttg	aggaggagga
agtgattatc	gagcaggacc	caggttttgt	aagcgaagac	gacgaggatc
gctcagtacc	aacagaggat	aaaaagcaag	accaggacga	cgcagaggca
aacgaggaac	aagtcggggc	gggggaccaa	aggcatggcg	actacctaga
tgtgggagac	gacgtgctgt	tgaagcatct	gcagcgccag	tgcgccatta
tctgcgacgc	gttgcaagag	cgcagcgatg	tgcccctcgc	catagcggat
gtcagccttg	cctacgaacg	ccacctgttc	tcaccgcgcg	taccccccaa
acgccaagaa	aacggcacat	gcgagcccaa	cccgcgcctc	aacttctacc
ccgtattttg	cgtgccagag	gtgcttgcca	cctatcacat	ctttttccaa
aactgcaaga	tacccctatc	ctgccgtgcc	aaccgcagcc	gagcggacaa
gcagctggcc	ttgcggcagg	gcgctgtcat	acctgatata	gcctcgctcg
acgaagtgcc	aaaaatcttt	gagggctctg	gacgcgacga	gaaacgcgcg
gcaaacgctc	tgcaacaaga	aaacagcgaa	aatgaaagtc	actgtggagt
gctggtggaa	cttgaggggtg	acaacgcgcg	cctagccgtg	ctgaaacgca
gcatcgagg	caccactttt	gcctacccgg	cacttaacct	accccccaag
gttatgagca	cagtcatgag	cgagctgata	gtgcgcctg	cacgaccctt
ggagagggat	gcaaacttgc	aagaacaaac	cgaggagggc	ctaccgcgag
ttggcgatga	gcagctggcg	cgctggcttg	agacgcgcga	gcctgccgac
ttggaggagc	gacgcaagct	aatgatggcc	gcagtgcctg	ttaccgtgga
gcttgagtgc	atgcagcgg	tctttgctga	cccggagatg	cagcgcaagc
tagaggaaac	gttgcaactac	acctttcgcc	agggctacgt	gcgccaggcc
tgcaaaat	ccaacgtgga	gctctgcaac	ctggtctcct	accttggaat
tttgacgaa	aaccgcctcg	ggcaaaacgt	gcttcattcc	acgctcaagg
gcgaggcgcg	ccgcgactac	gtccgcgact	gcgtttactt	atttctgtgc
tacacctggc	aaacggccat	gggcgtgtgg	cagcaatgcc	tggaggagcg
caacctaaag	gagctgcaga	agctgctaaa	gcaaaacttg	aaggacctat
ggacggcctt	caacgagcgc	tccgtggccg	cgcacctggc	ggacattatc
ttccccgaac	gcctgcttaa	aaccctgcaa	cagggctctg	cagacttcac
cagtcaaagc	atgttgcaaa	actttaggaa	ctttatccta	gagcgttcag
gaattctgcc	cgccacctgc	tgtgcgcttc	ctagcgactt	tgtgcccatt
aagtaccgtg	aatgccctcc	gccgctttgg	ggtcactgct	accttctgca
gctagccaac	taccttgctt	accactccga	catcatggaa	gacgtgagcg
gtgacggcct	actggagtgt	cactgtcgct	gcaacctatg	caccccgcac
cgctccctgg	tctgcaattc	gcaactgctt	agcgaaagtc	aaattatcgg
tacctttgag	ctgcagggtc	cctcgcttga	cgaaaagtcc	gcggctccgg
ggttgaaact	caactccggg	ctgtggacgt	cggcttacct	tcgcaaattt
gtacctgagg	actaccacgc	ccacgagatt	aggttctacg	aagaccaatc
ccgcccgcga	aatgcggagc	ttaccgcctg	cgtcattacc	cagggccaca
tccttgggcca	attgcaagcc	atcaacaaag	cccgcgaaga	gtttctgcta
cgaaagggac	gggggggtta	cctggacccc	cagtcggcg	aggagctcaa
cccaatcccc	ccgcccgcgc	agccctatca	gcagccgcgc	gcccttgctt
cccaggatgg	cacccaaaaa	gaagctgcag	ctgccgcgcg	cgccaccac
ggacgaggag	gaatactggg	acagtcaggc	agaggaggtt	ttggacgagg
aggaggagat	gatggaagac	tgggacagcc	tagacgaagc	ttccgaggcc
gaagaggtgt	cagacgaaac	accgtcaccc	tcggtcgc	tcccctcgcc

```

ggcgccccag aaattggcaa cgttccccag catcgctaca acctccgctc
ctcaggcgcc gccggcactg cctgttcgcc gacccaaccg tagatgggac
accactggaa ccagggccgg taagtctaa gacccgcgc cgttagccca
agagcaacaa cagcgccaag gctaccgctc gtggcgcggg cacaagaacg
ccatagttgc ttgcttgcaa gactgtgggg gcaacatctc cttcgcccg
cgctttcttc tctaccatca cggcggtggc ttcccccgta acatcctgca
ttactaccgt catctctaca gcccctactg caccggcggc agcggcagcg
gcagcaacag cagcggtcac acagaagcaa aggcgaccgg atagcaagac
tctgacaaag cccaagaaat ccacagcggc ggcagcagca ggaggaggag
cgctgcgtct gccgcccac gaacccgtat cgaccgcga gcttagaaat
aggatttttc ccactctgta tgctatat tcaacaaagca ggggccaaaga
acaagagctg aaaataaaaa acaggtctct gcgctccctc acccgagct
gcctgtatca caaaagcgaa gatcagcttc ggcgcacgct ggaagacgcg
gaggctctct tcagcaaata ctgcgcgctg actcttaagg actagtttcg
cgccctttct caaatttaag cgcgaaaact acgtcatctc cagcggccac
acccggcgcc agcacctgtc gtcagcgcca ttatgagcaa ggaaattccc
acgccctaca tgtggagtta ccagccacaa atgggacttg cggctggagc
tgcccaagac tactcaaccc gaataaacta catgagcgcg ggacccaca
tgatatcccg ggtcaacgga atccgcgccc accgaaaccg aattctctc
gaacaggcgg ctattaccac cacacctcgt aataacctta atccccgtag
ttggcccgct gccctggtgt accaggaaa gctccgctccc accactgtgg
tacttcccag agacgcccag gccgaagttc agatgactaa ctcagggcg
cagcttgcg gcggttttcg tcacagggtg cggtcgccc ggcgttttag
ggcgagtaaa cttgcatgta ttgggaattg tagttttttt aaaatgggaa
gtgacgtatc gtgggaaaac ggaagtgaag atttgaggaa gttgtgggtt
ttttggcttt cgtttctggg cgtagggttc cgtgcggttt tctgggtgtt
ttttgtggac tttaacgtt acgtcatttt ttagtcctat atatactgc
tctgtacttg gcccttttta cactgtgact gattgagctg gtgccgtgtc
gagtgggtgt ttttaatagg tttttttact ggtaaggctg actgttatgg
ctgccgctgt ggaagcgtg tatgtgttc tggagcgga ggggtctatt
ttgcctagggc aggagggttt ttcagggtgt tatgtgtttt tctctcctat
taattttgtt atacctcta tgggggctgt aatgttgtct ctacgcctgc
gggtatgtat tccccgggc tatttcggtc gcttttttag actgaccgat
gttaaccaac ctgatgtgtt taccgagtct tacattatga ctccggacat
gaccgaggaa ctgtcggtgg tgctttttta tcacggtgac cagttttttt
acggtcacgc cggcatggcc gtagtccgtc ttatgcttat aagggttgtt
tttctgtttg taagacaggc ttctaagtgt taaatgtttt tttttttgtt
atgtgttctt tttctgtgtt ggttccggaa cttacctgcc ttagagaaaa
tgagcatgac tacgatgtgc ttgctttttt gcgcgaggct tttatctgca
ttttgagcag caccttgcat tttatatcgc cgcctatgca ttgcctgatt
ataggggcta cgctggttag catagctccg agtatgcgtg ttcataatcag
tgtgggttct tttgtcatgg ttctggcg ggaagtggcc ggcgtggtcc
gtgcagacct gcacgattat gttcagctgg ccctgcgaag ggacctacgg
gatcgcggtt tttttgttaa tgttccgctt ttgaatctta tacaggctctg
tgaggaacct gaatttttgc aatcatgatt cgctgcttga ggctgaagg
ggagggcgct ctggagcaga tttttacaat ggccggactt aatattcggg
atgtgcttag agacatattg ataaggtggc gagatgaaa ttatttgggc
atggttgaag gtgctggaat gtttatagag gagattcacc ctgaagggtt
tagcctttac gtccacttgg acgtgagggc agtttgcctt ttggaagcca

```

ttgtgcaaca	tcttacaaat	gccattatct	gttcttttggc	tgtagagttt
gaccacgcca	ccggagggga	gcgcgttcac	ttaatagatc	ttcatttttga
ggtttttgat	aatctttttg	aataaaaaaa	aaaaaacatg	gttcttccag
ctcttcccgc	tcctcccgtg	tgtgactcgc	agaacgaatg	tgtaggttgg
ctgggtgtgg	cttattctgc	ggtggtggat	gttatcaggg	cagcggcgca
tgaaggagtt	tacatagaac	ccgaagccag	ggggcgccctg	gatgctttga
gagagtggat	atactacaac	tactacacag	agcgagctaa	gcgacgagac
cggagacgca	gatctgtttg	tcacgcccgc	acctggtttt	gcttcaggaa
atatgactac	gtccggcggtt	ccattttggca	tgacactacg	accaacacga
tctcggttgt	ctcggcgcac	tccgtacagt	agggatcgcc	tacctccttt
tgagacagag	accgcgcgcta	ccatactgga	ggatcatccg	ctgctgcccg
aatgtaacac	tttgacaatg	cacaacgtga	gttacgtgcg	aggtcctccc
tgcagtgtgg	gattttacgct	gattcaggaa	tgggttggtc	cctgggatat
ggttctgacg	cgggaggagc	ttgtaatcct	gaggaagtgt	atgcacgtgt
gcctgtgttg	tgccaacatt	gatatcatga	cgagcatgat	gatccatggt
tacgagtcct	gggctctcca	ctgtcattgt	tccagtccecg	gttccttgca
gtgcatagcc	ggcggggcagg	ttttggccag	ctggtttagg	atggtggtgg
atggcgccat	gtttaatcag	aggtttatat	ggtaccggga	ggtggtgaat
tacaacatgc	caaaagaggt	aatgtttatg	tccagcgtgt	ttatgagggg
tcgccactta	atctacctgc	gcttggtgga	tgatggccac	gtgggttctg
tgggtccccg	catgagcttt	ggatacagcg	ccttgcaactg	tgggattttg
aacaatatgg	tgggtgctgtg	ctgcagttac	tgtgctgatt	taagtgagat
caggggtgcgc	tgctgtgccc	ggaggacaag	gcgtctcatg	ctgcggggcg
tgcaaatcat	cgctgaggag	accactgcca	tgttgatttc	ctgcaggacg
gagcggcggc	ggcagcagtt	tattcgcgcg	ctgctgcagc	accaccgccc
tatcctgatg	cacgattatg	actctacccc	catgtaggcg	tggacttccc
cttcgccgcc	cgttgagcaa	cgcgaagtgt	gacagcagcc	tgtggctcag
cagctggaca	gcgacatgaa	cttaagcgag	ctgcccgggg	agtttattaa
tatcactgat	gagcgttttg	ctcgacagga	aaccgtgtgg	aatataacac
ctaagaatat	gtctgttacc	catgatatga	tgctttttta	ggccagccgg
ggagaaagga	ctgtgtactc	tgtgtgttgg	gagggaggtg	gcaggttgaa
tactagggtt	ctgtgagttt	gattaaggta	cggatgatcaa	tataagctat
gtgggtggtg	ggctatacta	ctgaatgaaa	aatgacttga	aattttctgc
aattgaaaaa	taaacacgtt	gaaacataac	atgcaacagg	ttcacgattc
tttattcctg	ggcaatgtag	gagaagggtg	aagagtttgt	agcaaaaagt
tcagtgggtg	attttccact	ttcccaggac	catgtaaaag	acatagagta
agtgcttacc	tcgctagttt	ctgtggattc	actagaatcg	atgtaggatg
ttgcccctcc	tgacgcggta	ggagaagggg	aggggtgccct	gcatgtctgc
cgctgctctt	gctcttgccg	ctgctgagga	ggggggcgca	tctgccgcag
caccggatgc	atctgggaaa	agcaaaaaag	gggctcgtcc	ctgtttccgg
aggaattttg	aagcggggtc	ttgcatgacg	gggaggcaaa	cccccgttcg
ccgcagtcgg	gccggccccg	gactcgaacc	gggggtcctg	cgactcaacc
cttgaaaaat	aaccctccgg	ctacaggggag	cgagccactt	aatgctttcg
ctttccagcc	taaccgctta	cgccgcgcgc	ggccagtggc	caaaaaagct
agcgcagcag	ccgccgcgcc	tggaaaggaag	ccaaaaggag	cgctcccccg
ttgtctgacg	tcgcacacct	gggttcgaca	cgcgggcggt	aaccgcatgg
atcacggcgg	acggccggat	ccgggggttcg	aaccccggtc	gtccgccatg
atacccttgc	gaatttatcc	accagaccac	ggaagagtgc	ccgcttacag
gctctccttt	tgcacggtct	agagcgtcaa	cgactgcgca	cgcctcaccg
gccagagcgt	cccgacctatg	gagcactttt	tgccgctgcg	caacatctgg

aaccgcgtcc	gcgactttcc	gcgcgcctcc	accaccgcgc	ccggcatcac
ctggatgtcc	aggtacatct	acggattacg	tcgacgttta	aaccatatga
tcagctcact	caaaggcggt	aatacgggta	tccacagaat	caggggataa
cgcaggaaag	aacatgtgag	caaaaggcca	gcaaaaggcc	aggaaccgta
aaaaggccgc	gttgctggcg	tttttccata	ggctccgccc	ccctgacgag
catcacaaaa	atcgacgctc	aagtcagagg	tggcgaaacc	cgacaggact
ataaagatac	caggcgtttc	cccctggaag	ctccctcggt	cgctctcctg
ttccgaccct	gccgcttacc	ggatacctgt	ccgcctttct	cccttcggga
agcgtggcgc	tttctcatag	ctcacgctgt	aggtatctca	gttcggtgta
ggtcgttcgc	tccaagctgg	gctgtgtgca	cgaaccccc	gttcagcccg
accgctgcgc	cttatccggt	aactatcgtc	ttgagtccaa	cccggtaaga
cacgacttat	cgccactggc	agcagccact	ggtaacagga	ttagcagagc
gaggtatgta	ggcgggtgcta	cagagttctt	gaagtgggtg	cctaactacg
gctacactag	aagaacagta	tttggtatct	gcgctctgct	gaagccagtt
accttcggaa	aaagagttgg	tagctcttga	tccggcaaac	aaaccaccgc
tggtagcggt	ggtttttttg	tttgcaagca	gcagattacg	cgcagaaaaa
aaggatctca	agaagatcct	ttgatctttt	ctacggggtc	tgacgctcag
tggaacgaaa	actcacgtta	agggattttg	gtcatgagat	tatcaaaaag
gatcttcacc	tagatccttt	taaattaaaa	atgaagtttt	aatcaatct
aaagtatata	tgagtaaact	tgggtctgaca	gtcagaagaa	ctcgtcaaga
aggcgataga	aggcgatgcg	ctgcgaatcg	ggagcggcga	taccgtaaag
cacgaggaag	cggtcagccc	attcgccgcc	aagctcttca	gcaatatcac
gggtagccaa	cgctatgtcc	tgatagcggg	ccgccacacc	cagccggcca
cagtcgatga	atccagaaaa	gcggccattt	tccaccatga	tattcggcaa
gcaggcatcg	ccatgggtca	cgacgagatc	ctcgccgtcg	ggcatgctcg
ccttgagcct	ggcgaacagt	tgggctggcg	cgagcccctg	atgctcttcg
tccagatcat	cctgatcgac	aagaccggct	tccatccgag	tacgtgctcg
ctcgatgcga	tgtttcgctt	ggtggtcgaa	tgggcaggta	gccggatcaa
gcgtatgcag	ccgccgcatt	gcatacagca	tgatggatac	tttctcggca
ggagcaagggt	gagatgacag	gagatcctgc	cccggcactt	cgcccaatag
cagccagtc	cttcccgcct	cagtgcacaac	gtcgagtaca	gctgcgcaag
gaacgcccgt	cgtggccagc	cacgatagcc	gcgctgcctc	gtcttgcaat
tcattcagggt	caccggacag	gtcgggtctt	acaaaaagaa	ccgggcccgc
ctgcgctgac	agccggaaca	cggcggcatc	agagcagccg	attgtctggt
gtgcccagtc	atagccgaat	agcctctcca	cccaagcggc	cggagaacct
gcgtgcaatc	catcttggtc	aatcatactc	ttcctttttc	aatattattg
aagcatttat	cagggttatt	gtctcatgag	cggatacata	tttgaatgta
tttagaaaaa	taaacaaata	ggggttccgc	gcacatttcc	ccgaaaagtg
ccacctaaat	tgtaagcggt	aatattttgt	taaaattcgc	gttaaatttt
tgttaaataca	gctcattttt	taaccaatag	gccgaaatcg	gcaaaatccc
ttataaatca	aaagaataga	ccgagatagg	gttgagtgtt	gttccagttt
ggaacaagag	tccactatta	aagaacgtgg	actccaacgt	caaagggcga
aaaaccgtct	atcagggcga	tggcccacta	cgtgaaccat	caccctaata
aagttttttg	gggtcgaggt	gccgtaaagc	actaaatcgg	aaccctaag
ggagcccccg	atttagagct	tgacggggaa	agccggcgaa	cgtggcgaga
aaggaaggga	agaaagcgaa	aggagcgggc	gctagggcgc	tggcaagtgt
agcggtcacg	ctgcgcgtaa	ccaccacacc	cgccgcgctt	aatgcgccgc
tacagggcgc	gatggatcc			

[0066] In SEQ ID NO:2, residues 1-5343 of **pHelper-Kan** are derived from adenovirus, and include a polynucleotide encoding the **E2A** protein (residues 258-1847); residues 5344-8535 are derived from adenovirus, and include a polynucleotide encoding the **E4orf6** protein; residues 9423-10011 correspond to ori sequences; residues 10182-10976 encode a kanamycin resistance determinant expressed by a *bla* promoter sequence (residues 10977-11081); residues 11107-11561 correspond to fl ori sequences (**Figure 5**).

[0067] As discussed above, **AAV helper function-providing polynucleotides** and **non-AAV helper function-providing polynucleotides** are typically employed in concert with an rAAV plasmid vector to comprise a triple plasmid transfection system. Multiple commercially available rAAV plasmid vectors (*e.g.*, **pAV-CMV-EGFP**, **pGOI**, *etc.* (Cell Biolabs, Inc., Invitrogen and Stratagene)) may be used in accordance with the present invention. An illustrative rAAV plasmid vector that may be used in accordance with the present invention is **pAV-CMV-EGFP (SEQ ID NO:3; Figure 6)** which comprises a 5' ITR, a U6 promoter, CMV enhancer and promoter sequences, a polynucleotide encoding the enhanced green fluorescent protein (**EGFP**) (Gambotto, A. *et al.* (2000) "Immunogenicity Of Enhanced Green Fluorescent Protein (EGFP) In BALB/C Mice: Identification Of An H2-Kd-Restricted CTL Epitope," *Gene Ther.* 7(23):2036-2040; Tsien, R.Y. (1998) "The Green Fluorescent Protein," *Annu. Rev. Biochem.* 67:509-544; Cinelli, R.A. *et al.* (2000) "The Enhanced Green Fluorescent Protein As A Tool For The Analysis Of Protein Dynamics And Localization: Local Fluorescence Study At The Single-Molecule Level," *Photochem. Photobiol.* 71(6):771-776; Chopra A. (2008) "Recombinant Adenovirus With Enhanced Green Fluorescent Protein," In: MOLECULAR IMAGING AND CONTRAST AGENT DATABASE (MICAD), National Center for Biotechnology Information, Bethesda MD), FLAG-tag and 6xHis-tag sites for facilitating recovery or localization of expressed proteins, an SV40 poly(A) site and a 3' ITR.

Coding Strand of Plasmid pAV-CMV-EGFP (SEQ ID NO:3):

```
cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcgctcg
ggcgaccttt ggtcgcccgg ccctccagtg agcgagcgcg cagagagggga
gtggccaact ccatcactag gggttcctgc ggccgcacgc gtctagttat
taatagtaat cgaattcgtg ttactcataa ctagtaaggt cgggcaggaa
gagggcctat ttcccatgat tccttcatat ttgcatatac gatacaaggc
tgtagagag ataattagaa ttaatttgac tgtaaacaca aagatattag
tacaaaatac gtgacgtaga aagtaataat ttcttgggta gtttgcagtt
```

ttaaaattat	gtttttaaaat	ggactatcat	atgcttaccg	taacttgaaa
gtatttgcgat	ttcttgggtt	tatatatctt	gtggaaagga	cgcgggatcc
actggaccag	gcagcagcgt	cagaagactt	ttttggaaaa	gcttgactag
taatactgta	atagtaatca	attacggggt	cattagttca	tagcccatat
atggagttcc	gcgttacata	acttacggta	aatggcccg	ctggctgacc
gccaacgac	ccccgccc	tgacgtcaat	aatgacgtat	gttcccatag
taacgccaat	agggactttc	cattgacgtc	aatgggtgga	gtatttacgg
taaactgcc	acttggcagt	acatcaagt	tatcatatgc	caagtacgcc
ccctattgac	gtcaatgacg	gtaaatggcc	cgctggcat	tatgcccagt
acatgacctt	atgggacttt	cctacttggc	agtacatcta	cgtattagtc
atcgctatta	ccatgggtgat	gcggttttgg	cagtacatca	atgggctggt
atagcggttt	gactcacggg	gatttccaag	tctccacccc	attgacgtca
atgggagttt	gttttgcacc	aaaatcaacg	ggactttcca	aaatgtcgta
acaactccgc	cccattgacg	caaatggg	gtaggcgtgt	acgggtgggag
gtctatataa	gcagagctgg	tttagtgaac	cgtcagatcc	gctagagatc
cggtagccag	gagatctgcc	gccgcgatcg	ccggcgcgcc	agatctcacg
cttaactagc	tagcggaccg	acgcgtacgc	ggccgctcga	gatggtgagc
aagggcgagg	agctgttcac	cggggtggtg	cccatcctgg	tcgagctgga
cggcgacgta	aacggccaca	agttcagcgt	gtccggcgag	ggcgagggcg
atgccaccta	cggcaagctg	accctgaagt	tcctctgcac	caccggcaag
ctgcccgtgc	cctggcccac	cctcgtgacc	accctgacct	acggcgtgca
gtgcttcagc	cgctacccc	accacatgaa	gcagcacgac	ttcttcaagt
ccgccatgcc	cgaaggctac	gtccaggagc	gcaccatctt	cttcaaggac
gacggcaact	acaagaccg	cgccgaggtg	aagtctgagg	gcgacaccct
ggtgaaccgc	atcgagctga	agggcatcga	cttcaaggag	gacggcaaca
tcctggggca	caagctggag	tacaactaca	acagccacaa	cgtctatata
atggccgaca	agcagaagaa	cggcatcaag	gtgaacttca	agatccgcca
caacatcgag	gacggcagcg	tgcagctcgc	cgaccactac	cagcagaaca
cccccatcgg	cgacggcccc	gtgctgctgc	ccgacaacca	ctacctgagc
accagtcgg	ccctgagcaa	agaccccaac	gagaagcgcg	atcacatggt
cctgctggag	ttcgtgaccg	ccgccgggat	cactctcggc	atggacgagc
tgtacaagta	agtcgaggat	tataaggatg	acgacgataa	attcgtcgag
caccaccacc	accaccacta	ataaggttta	tccgatccac	cggatctaga
taagatatcc	gatccaccgg	atctagataa	ctgatcataa	tcagccatac
cacatttgta	gaggttttac	ttgcttttaa	aaacctccca	cacctcccc
tgaacctgaa	acataaaatg	aatgcaattg	ttgttggtta	cttgtttatt
gcagcttata	atggttacaa	ataaagcaat	agcatcacia	atttcacaaa
taaagcattt	ttttactgc	attctagttg	tggtttgtcc	aaactcatca
atgtatctta	acgcggtaac	cacgtgcgga	ccgagcggcc	gcaggaaccc
ctagtgatgg	agttggccac	tccctctctg	cgcgctcgct	cgctcactga
ggccgggcca	ccaaaggctc	cccgcgccc	gggctttgcc	cgggcggcct
cagtgagcga	gcgagcgcgc	agctgcctgc	aggggcgcct	gatgcggtat
tttctcctta	cgcatctgtg	cggatatttca	caccgcatac	gtcaaagcaa
ccatagtacg	cgccctgtag	cggcgcatta	agcgcggcgg	gtgtggtggt
tacgcgcagc	gtgaccgcta	cacctgccag	cgcttagcgg	cccgtcctt
tcgctttctt	cccttctttt	ctcgccacgt	tcgcccggctt	tccccgtcaa
gctctaaatc	gggggctccc	tttaggggtt	cgatttagtg	ctttacggca
cctcgacccc	aaaaaacttg	atgtgggtga	tggttcacgt	agtgggccat
cgccctgata	gacggttttt	cgccctttga	cgttggagtc	cacgttcttt
aatagtggac	tcttgttcca	aactggaaca	acactcaacc	ctatctcggg

```

ctatttctttt gatttataag ggatttttgcc gatttctggcc tatttggttaa
aaaatgagct gatttaacaa aaattttaacg cgaatttttaa caaaatatta
acgttttaca ttttatggtg cactctcagt acaatctgct ctgatgccgc
atagtttaagc cagccccgac acccgccaac acccgctgac gcgccctgac
gggcttgctt gctcccggca tccgcttaca gacaagctgt gaccgtctcc
gggagctgca tgtgtcagag gttttcaccg tcatcaccga aacgcgcgag
acgaaagggc ctcgatgatac gcctattttt ataggttaat gtcataataa
taatggtttc ttagacgtca ggtggcactt ttcggggaaa tgtgcgcgga
accctatatt gtttattttt cttaaatacat tcaaataatgt atccgctcat
gagacaataa ccctgataaa tgcttcaata atattgaaaa aggaagagta
tgagtattca acatttccgt gtcgccctta ttcccttttt tgcggcattt
tgccttcctg tttttgctca cccagaaaac ctggtgaaaag taaaagatgc
tgaagatcag ttgggtgcac gagtgggtta catcgaactg gatctcaaca
gcggttaagat ccttgagagt tttcgccccg aagaacgttt tccaatgatg
agcactttta aagtctctgt atgtggcgcg gtattatccc gtattgacgc
cgggcaagag caactcggtc gccgcataca ctattctcag aatgacttgg
ttgagtactc accagtcaca gaaaagcatc ttacggatgg catgacagta
agagaattat gcagtgtctc cataaccatg agtgataaca ctgcggccaa
cttacttctg acaacgatcg gaggaccgaa ggagctaacc gcttttttgc
acaacatggg ggatcatgta actcgccttg atcgttggga accggagctg
aatgaagcca taccaaacga cgagcgtgac accacgatgc ctgtagcaat
ggcaacaacg ttgcgcaaac tattaactgg cgaactactt actctagctt
ccgggcaaca ataatagac tggatggagg cggataaagt tgcaggacca
cttctgcgct cggcccttcc ggctggctgg tttattgctg ataaatctgg
agccggtgag cgtgggtctc gccgtatcat tgcagcactg gggccagatg
gtaagccctc ccgtatcgta gttatctaca cgacggggag tcaggcaact
atggatgaac gaaatagaca gatcgtgag atagggtgct cactgattaa
gcattggtaa ctgtcagacc aagtttactc atatatactt tagattgatt
taaaacttca tttttaattt aaaaggatct aggtgaagat cctttttgat
aatctcatga ccaaaatccc ttaacgtgag ttttcgttcc actgagcgtc
agaccccgta gaaaagatca aaggatcttc ttgagatcct ttttttctgc
gcgtaatctg ctgcttgcaa acaaaaaaac caccgctacc agcgggtggtt
tgtttgccgg atcaagagct accaactctt tttccgaagg taactggctt
cagcagagcg cagataccaa ataactgtcct tctagtgtag ccgtagttag
gccaccactt caagaactct gtagcaccgc ctacatacct cgctctgcta
atcctgttac cagtggctgc tgccagtggc gataagtcgt gtcttaccgg
gttggtactca agacgatagt taccggataa ggcgcagcgg tcgggctgaa
cgggggggtt gtgcacacag cccagcttgg agcgaacgac ctacaccgaa
ctgagatacc tacagcgtga gctatgagaa agcgccacgc tttccgaagg
gagaaaggcg gacaggtatc cggtaagcgg cagggtcgga acaggagagc
gcacgagggg gcttccaggg ggaaacgcct ggtatcttta tagtcctgtc
gggtttcgcc acctctgact tgagcgtcga tttttgtgat gctcgtcagg
ggggcgagc ctatggaaaa acgccagcaa cgcggccttt ttacgggttcc
tggccttttg ctggcctttt gctcacatgt

```

[0068] In SEQ ID NO:3, residues 1-128 of pAV-CMV-EGFP correspond to the 5' ITR; residues 201-441 are U6 promoter sequences; residues 562-865 are human cytomegalovirus (CMV) immediate early enhancer sequences; residues 866-1068

comprise the CMV immediate early promoter; residues 1192-1911 comprise a mammalian codon-optimized polynucleotide that encodes the EGFP; residues 1918-1941 encode the FLAG-tag; residues 1951-1968 encode the 6xHis-tag; residues 2139-2260 encode the SV40 poly(A) sequence; residues 2293-2433 correspond to the 3' ITR; residues 2508-22963 correspond to F1 ori sequences; residues 3350-4210 encode an ampicillin resistance determinant and its signal sequence (residues 3350-3418) expressed by a *bla* promoter sequence (residues 3245-3349); residues 4381-4969 correspond to an ori sequence (**Figure 6**).

[0069] A second illustrative rAAV plasmid vector that may be used in accordance with the present invention is **pAV-TBG-EGFP (SEQ ID NO:4; Figure 7)** which comprises a 5' ITR, a thyroid hormone-binding globulin (TBG) promoter, a polynucleotide encoding the enhanced green fluorescent protein (EGFP), FLAG-tag and 6xHis-tag sites for facilitating recovery or localization of expressed proteins, an SV40 poly(A) site and a 3' ITR.

Coding Strand of Plasmid pAV-TBG-EGFP (SEQ ID NO:4):

```

cctgcaggca gctgcgcgct cgctcgctca ctgaggccgc ccgggcgtcg
ggcgaccttt ggtcgcccgg cctcagtgag cgagcgagcg cgcagagagg
gagtggccaa ctccatcact aggggttcct gcggccgggtc gcgtctagta
ctagtagggtt aattttttaa aagcagtcaa aagtccaagt ggcccttggc
agcatttact ctctctgttt gctctggtta ataattctcag gagcacaac
attccagatc caggttaatt tttaaaaagc agtcaaaagt ccaagtggcc
cttggcagca ttactctct ctgtttgctc tgggtaataa tctcaggagc
acaacattc cagatccggc gcgccagggc tggaagctac ctttgacatc
atttcctctg cgaatgcatg tataatttct acagaaccta ttagaaagga
tcaccagcc tctgcttttg tacaactttc ccttaaaaaa ctgccaatc
cactgctgtt tggcccaata gtgagaactt tttcctgctg cctcttggtg
cttttgccct tggcccctat tctgcctgct gaagacactc ttgccagcat
ggacttaaac ccctccagct ctgacaatcc tctttctctt ttgttttaca
tgaagggtct ggcagccaaa gcaatcactc aaagtccaac ccttatcatt
ttttgctttg ttctctttgg ccttggtttt gtacatcagc ttgaaaata
ccatcccagg gttaatgctg ggggttaattt ataactaaga gtgctctagt
tttgcaatac aggacatgct ataaaaatgg aaagatggtt ctttctgaga
gacagggtacc gaggagatct gccgccgcga tcgccaccat ggtgagcaag
ggcgaggagc tggtcaccgg ggtgggtgcc atcctgggtc agctggacgg
cgacgtaaac ggccacaagt tcagcgtgtc cggcgagggc gagggcgatg
ccacttacgg caagctgacc ctgaagttca tctgcaccac cggcaagctg
cccgtgccct ggcccaccct cgtgaccacc ctgacctacg gcgtgcagtg
cttcagccgc taccgacc acatgaagca gcacgacttc ttcaagtccg
ccatgcccga aggtacgtc caggagcgca ccatcttctt caaggacgac
ggcaactaca agaccgcgc cgaggtgaag ttcgagggcg acaccctggg
gaaccgcata gagctgaagg gcatcgactt caaggaggac ggcaacatcc
tggggcacaa gctggagtac aactacaaca gccacaacgt ctatatcatg

```

```

gccgacaagc agaagaacgg catcaagggt aacttcaaga tccgccacaa
catcgaggac ggcagcgtgc agctcgccga ccactaccag cagaacaccc
ccatcggcga cggccccgtg ctgctgcccg acaaccacta cctgagcacc
cagtcgcgcc tgagcaaaga ccccaacgag aagcgcgata acatggtcct
gctggagtgc gtgaccgccc cggggatcac tctcggcatg gacgagctgt
acaagtagac gcgtagcggg ccgctcgagg attataagga tgacgacgat
aaattcgtcg agcaccacca ccaccaccac taataagggt tatccgatcc
accgatctta gataagatat ccgatccacc ggatctagat aactgatcat
aatcagccat accacatttg tagagggttt acttgcttta aaaaacctcc
cacacctccc cctgaacctg aaacataaaa tgaatgcaat tgttggtgtt
aacttgctta ttgcagctta taatgggttac aaataaagca atagcatcac
aaatttcaca aataaagcat ttttttctact gcattctagt tgtggtttgt
ccaaactcat caatgtatct taacgcggta accacgtgcg gacccaacgg
ccgcaggaac ccctagtgat ggagttggcc actccctctc tgcgcgctcg
ctcgctcact gaggcggggc gaccaaaggt cggccgacgc ccgggctttg
ccggggcggc ctcagtgcgc gagcgcgcgc gcagctgcct gcagggcggc
ctgatgcggg attttctcct tacgcctctg tgcggtatct cacaccgat
acgtcaaagc aaccatagta cgcgcctgt agcggcacat taagcgcggc
gggtgtggtg gttacgcgca gcgtagccgc tacacctgcc agcgccttag
cgcccgctcc tttcgctttc ttcccttctt ttctcgccac gttcgccggc
tttcccgcgc aagctctaaa tcgggggctc ctttaggggt tccgatttag
tgctttacgg cacctcgacc ccaaaaaact tgatttgggt gatggttcac
gtagtgggac atcgccctga tagacgggtt ttcgcccttt gacgttggag
tccaggttct ttaatagtgg actcttggtc caaactggaa caaactcaa
ctctatctcg ggctattctt ttgatttata agggattttg ccgatttcgg
tctattgggt aaaaaatgag ctgatttaac aaaaatttaa cgcgattttt
aacaaaatat taacgtttac aattttatgg tgcactctca gtacaatctg
ctctgatgcc gcatagttaa gccagccccg acaccgcga acaccgcgtg
acgcgccttg acgggcttgt ctgctcccgg catccgctta cagacaagct
gtgaccgtct ccgggagctg catgtgtcag aggttttcac cgtcatcacc
gaaacgcgcg agacgaaagg gcctcgatg acgcctatct ttatagggtta
atgtcatgat aataatgggt tcttagacgt cagggtggac ttttcgggga
aatgtgcgcg gaacccttat ttgtttatct ttctaaatac attcaaatat
gtatccgctc atgagacaat aaccctgata aatgcttcaa taatattgaa
aaaggaagag tatgagtatt caacatttcc gtgtcgccct tattcccttt
tttgcggcat tttgccttcc tgtttttgct caccagaaa cgctggtgaa
agtaaaagat gctgaagatc agttgggtgc acgagtgggt tacatcgaa
tgatctcaa cagcggtaag atccttgaga gttttcgccc cgaagaacgt
tttccaatga tgagcacttt taaagttctg ctatgtggcg cgttattatc
ccgtattgac gccgggcaag agcaactcgg tcgccgcata cactattctc
agaatgactt gggtgagtac tcaccagtca cagaaaagca tcttacggat
ggcatgacag taagagaatt atgcagtgt gccataacca tgagtataa
cactgcggcc aacttacttc tgacaacgat cggaggaccg aaggagctaa
ccgctttttt gcacaacatg ggggatcatg taactcgctt tgatcggttg
gaaccggagc tgaatgaagc cataccaaac gacgagcgtg acaccacgat
gcctgtagca atggcaacaa cgttgcgcaa actattaact ggcaactac
ttactctagc ttccgggcaa caattaatag actggatgga ggcggataaa
gttgacggac cacttctgcg ctcgccctt ccggctggct ggtttattgc
tgataaatct ggagccgggt agcgtgggtc tcgcggtatc attgcagcac
tggggccaga tggtaagccc tcccgtatcg tagttatcta cacgacgggg

```

```

agtcaggcaa ctatggatga acgaaataga cagatcgctg agataggtgc
ctcactgatt aagcattggt aactgtcaga ccaagtttac tcatatatac
tttagattga tttaaaactt catttttaat ttaaaaggat ctagggtgaag
atcctttttg ataatctcat gaccaaatac ccttaacgtg agttttcggt
ccactgagcg tcagaccccg tagaaaagat caaaggatct tcttgagatc
ctttttttct gcgcgtaatc tgctgcttgc aaacaaaaaa accaccgcta
ccagcgggtg tttgtttgcc ggatcaagag ctaccaactc tttttccgaa
ggtaactggc ttcagcagag cgcagatacc aaatactggt cttctagtgt
agccgtagtt aggccaccac ttcaagaact ctgtagcacc gcctacatac
ctcgtctctg taatcctggt accagtggct gctgccagtg gcgataagtc
gtgtcttacc ggggttgact caagacgata gttaccggat aaggcgcagc
ggtcgggctg aacggggggt tcgtgcacac agcccagctt ggagcgaacg
acctacaccg aactgagata cctacagcgt gagctatgag aaagcggcac
gcttcccga gggagaaagg cggacaggta tccggtaagc ggcagggtcg
gaacaggaga gcgcacgagg gagcttccag ggggaaacgc ctggtatctt
tatagtcttg tcgggtttcg ccacctctga cttgagcgtc gatttttgtg
atgctcgta ggggggcgga gcctatggaa aaacgccagc aacgcggcct
ttttacgggt cctggccttt tgctggcctt ttgctcacat gt

```

[0070] In **SEQ ID NO:4**, residues 1-130 of **pAV-TBG-EGFP** correspond to the 5' ITR; residues 150-854 are TBG promoter sequences, with residues 415-824 comprising the TBG promoter; residues 886-1608 encode the EGFP; residues 1630-1653 encode the FLAG-tag; residues 1663-1680 encode the 6xHis-tag; residues 1851-1972 encode the poly(A) sequence; residues 2005-2145 corresponds to the 3' ITR; residues 2220-2675 correspond to F1 ori sequences; residues 3062-3922 encode an ampicillin resistance determinant and its signal sequence (residues 3062-3130) expressed by a *bla* promoter sequence (residues 2957-3061); residues 4093-4681 correspond to an ori sequence (**Figure 7**).

[0071] In particular, the present invention provides a recombinantly-modified adeno-associated virus (rAAV), such as **pAV-CMV-EGFP** or **pAV-TBG-EGFP**, that comprises a Cis-Element in one or more of its **P1**, **P2**, **P3** or **P4 Domains**, wherein:

- (1) the **P1 Domain** is 5' to a 5' ITR of the rAAV;
- (2) the **P2 Domain** is 3' to the 5' ITR of the rAAV and 5' to a transgene cassette of the rAAV;
- (3) the **P3 Domain** is 3' to the transgene cassette of the rAAV and 5' to a 3' ITR of the rAAV; and
- (4) the **P4 Domain** is 3' to the 3' ITR of the rAAV; and

wherein the presence of the Cis-Element causes rAAV-producing cells to produce the rAAV at a higher production titer than would be attained with such rAAV if lacking the Cis-Element.

[0072] In one embodiment, the Cis-Element will preferably comprise an introduced nucleotide sequence that was not previously present in rAAV vector. In other embodiments, the introduced nucleotide sequence was previously present in such rAAV plasmid vector, and has been positioned in the recombinantly-produced rAAV plasmid vector, adjacent to, or immediately adjacent to, such previously present nucleotide sequence. Alternatively, such introduced nucleotide sequence may be positioned at a site that is not adjacent to such previously present nucleotide sequence.

[0073] As shown in **Figure 8**, an rAAV or an rAAV plasmid vector of the present invention may be envisioned as having, in the 5' to 3' direction:

- (1) the 5' terminus of the rAAV;
- (2) a polynucleotide region (the "**P1 Domain**")
- (3) a "**5' ITR**," which is an ITR that is located at or near the 5' end of the polynucleotide chain that comprises the coding strand of the transgene cassette of the rAAV;
- (4) a polynucleotide region (the "**P2 Domain**")
- (5) a transgene cassette (including a preceding (*i.e.*, 5'-positioned) promoter ("**Pro**"), the transgene encoding sequence ("**Gene**"), and following (*i.e.*, 3'-positioned) poly-A sequence ("**PolyA**");
- (6) a polynucleotide region (the "**P3 Domain**")
- (7) a "**3' ITR**," which is an ITR that is located at or near the 3' end of the polynucleotide chain that comprises the coding strand of the transgene cassette of the rAAV;
- (8) a polynucleotide region (the "**P4 Domain**"); and
- (9) the 3' terminus of the rAAV."

[0074] Such **P1**, **P2**, **P3**, and **P4 Domains** need not all be present in any particular rAAV or rAAV plasmid vector, and an rAAV or rAAV plasmid vector may lack any 1, 2, or 3 of these Domains, or may lack all 4 of such Domains. The boundaries of such Domains are defined by the other domains of the rAAV or rAAV plasmid vector. Thus,

the **P1 Domain** extends from the 5' terminus of the rAAV or rAAV plasmid vector to the 5' terminus of the 5' ITR. The **PciI** site of **pAV-CMV-EGFP** or **pAV-TBG-EGFP** is an example of a suitable site within the **P1 Domain** of an rAAV or rAAV plasmid vector for insertion of a Cis-Element. The **P2 Domain** extends from the 3' terminus of the 5' ITR to the 5' terminus of the transgene cassette. The **P3 Domain** extends from the 3' terminus of the transgene cassette to the 5' terminus of the 3' ITR. The **EcoRI** site of **pAV-CMV-EGFP** or the **SpeI** site of **pAV-TBG-EGFP** are examples of suitable sites within the **P2 Domain** of an rAAV or rAAV plasmid vector for insertion of a Cis-Element. The **P3 Domain** extends from the 3' terminus of the poly(A) sequence to the 3' ITR of the rAAV or rAAV plasmid vector. The **PmlI** site of **pAV-CMV-EGFP** or **pAV-TBG-EGFP** is an example of a suitable site within the **P3 Domain** of an rAAV or rAAV plasmid vector for insertion of a Cis-Element. The **P4 Domain** extends from the 3' terminus of the 3' ITR to the 3' terminus of the rAAV or rAAV plasmid vector. The **KasI** site of **pAV-CMV-EGFP** or **pAV-TBG-EGFP** is an example of a suitable site within the **P4 Domain** of an rAAV or rAAV plasmid vector for insertion of a Cis-Element. The precise location of a Cis-Element of the present invention within a particular **P1**, **P2**, **P3**, or **P4 Domain** is not material to the ability of such positioned Cis-Element to mediate an increase in rAAV production titers. Insertions of Cis-Element(s) may be made by ligating a Cis-Element into a suitable restriction site or by employing primers to install such Cis-Elements.

[0075] The present invention employs the nomenclature of CisE1, CisE2, *etc.* to identify particular Cis-Elements. Such designation is followed by "For" or "Rev" in some cases to indicate that the Cis-Element is being (respectively) inserted into the rAAV in its forward orientation or in its reverse orientation. When "For" or "Rev" are not indicated, the Cis-Element is being inserted into the rAAV in its forward orientation. Lastly, the present invention employs the nomenclature **P1**, **P2**, **P3**, or **P4 Domain** to indicate the domain within which the Cis-Element has been inserted. Thus, for example, an rAAV or rAAV plasmid vector containing Cis-Element CisE1 of the present invention within its **P1 Domain** in its forward orientation is referred to herein by the designation "**CisE1-For-P1**" or "**CisE1-P1**;" an rAAV or rAAV plasmid vector containing Cis-Element CisE21 of the present invention within its **P2 Domain** in its forward orientation is referred to herein by the designation "**CisE21-For-P2**" or

“**CisE1-P2**,” an rAAV or rAAV plasmid vector containing Cis-Element CisE30 of the present invention within its **P4 Domain** in its reverse orientation is referred to herein by the designation “**CisE30-Rev-P4**.” Thus, with reference to the constructs shown schematically in **Figure 8**, constructs CisE-P1, CisE-Rev-P1, CisE-P1&P4, CisE-P1~P4 all contain Cis-Elements within the **P1 Domain** (the orientation of the Cis-Element may be reversed, as in CisE-Rev-P1); the construct CisE-P1&P4 contains Cis-Elements within the **P1 Domain** and within the **P4 Domain**; the construct CisE-P1~P4 contains Cis-Elements within the **P1, P2, P3** and **P4 Domains**.

[0076] In one embodiment, such Cis-Elements are actual or potential “**G-Quadruplex Sequences**” capable of forming a **G-Quadruplex Structure**. The G-Quadruplex Structures of particular relevance to the present invention comprise only a single polynucleotide chain, and have the general formula of four series, each composed of 3 or more deoxyguanosine residues, wherein the first, second and third such series is separated from the fourth such series by from 1 to 7 of any other nucleotide residue.

[0077] In some cases, a particular polynucleotide will comprise a sequence that is known to comprise a G-Quadruplex Sequence (*i.e.*, an “**Actual G-Quadruplex Sequence**”). In other cases, a particular sequence will be predicted to comprise a G-Quadruplex Sequence that can form a G-Quadruplex Structure (*i.e.*, a “**Potential G-Quadruplex Sequence**”). Predictive algorithms for determining whether any particular polynucleotide is a potential G-Quadruplex Sequence are well known, and thus the recognition of whether a particular polynucleotide is a potential G-Quadruplex Sequence may be readily accomplished. Examples of such predictive algorithms include **G4P Calculator** (Eddy, J. *et al.* (2006) “*Gene Function Correlates With Potential For G4 DNA Formation In The Human Genome*,” Nucleic Acids Res. 34:3887-3896), **QuadParser** (Huppert, J.L. *et al.* (2005) “*Prevalence Of Quadruplexes In The Human Genome*,” Nucleic Acids Res. 33:2908-29168) and **GHunter** (Bedrat, A. *et al.* (2016) “*Re-evaluation of G-Quadruplex propensity with G4Hunter*,” Nucleic Acids Res. 44(4):1746-1759), have been developed to identify potential G-Quadruplex Sequences (Huppert, J.L. *et al.* (2007) “*G-Quadruplexes In Promoters Throughout The Human Genome*,” Nucleic Acids Res. 35:406-413; Verma, A. *et al.* (2008) “*Genome-Wide Computational And Expression Analyses Reveal G-Quadruplex DNA Motifs As*

Conserved Cis-Regulatory Elements In Human And Related Species,” J. Med. Chem. 51:5641-5649).

[0078] The invention further encompasses compositions such as plasmids that are genetically engineered to replicate high levels of recombinant viral genomes. The replication of viral genomes may be regulated through the use of Cis-Elements, including replication origins, promoters and enhancers. Such Cis-Elements can be genetically engineered into recombinant plasmids that are designed to pack AAV vectors. Further, the invention encompasses the Cis-Elements can be located before or after ITRs.

[0079] Cis-elements of the present invention that increase AAV production particularly include:

- (1) Potential G-Quadruplex Sequences of wild type AAV genomes (*e.g.*, CisE1 – CisE16 (**SEQ ID NOs:5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33 and 35**)), or Potential G-Quadruplex Sequences in a reversed orientation (*e.g.*, CisE1-Rev – CisE16-Rev (**SEQ ID NOs:6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34 and 36**));
- (2) Actual G-Quadruplex Sequences (*e.g.*, CisE17 – CisE20 (**SEQ ID NOs:37, 39, 41 and 43**)) or Actual G-Quadruplex Sequences in a reversed orientation (*e.g.*, CisE17-Rev – CisE20-Rev (**SEQ ID NOs:38, 40, 42 and 44**));
- (3) Other DNA sequences from wild-type AAV (*e.g.*, CisE21 – CisE26 and CisE31 – CisE35 (**SEQ ID NOs:45, 47, 49, 51, 53, 55, 65, 67, 69, 71 and 73**)) or other DNA sequences from wild-type AAV in a reversed orientation (*e.g.*, CisE21-Rev – CisE26-Rev and CisE31-Rev – CisE35-Rev (**SEQ ID NOs: 46, 48, 50, 52, 54, 56, 66, 68, 72 and 74**)); and
- (4) DNA sequences from other viral genomes (*e.g.*, CisE27 – CisE30 (**SEQ ID NOs:57, 59, 61 and 63**)) or such DNA sequences from other viral sources in a reversed orientation (*e.g.*, CisE27-Rev – CisE30-Rev (**SEQ ID NOs: 58, 60, 62 and 64**)) and human genomes.

[0080] **Table 1** provides the sequences, sequence designations, and origins of such preferred exemplary Cis-Elements of the present invention.

SEQ ID NO	Sequence Designation	Source or Origin	Sequence
5	CisE1	GQ4	gggtggccga gaaggaatgg
6	CisE1-Rev	GQ4-Rev	ggtaaggaag agccggtggg
7	CisE2	GQ5	ggaatggcgc cgtgtgagta aggccccgg
8	CisE2-Rev	GQ5-Rev	ggccccggaa tgagtgtgcc gcggttaagg
9	CisE3	GQ6	ggaaaccacc ggggtgaaat ccatgg
10	CisE3-Rev	GQ6-Rev	ggtacctaaa gtggggccac caaagg
11	CisE4	GQ7	ggagggcgga acaaggtggt gg
12	CisE4-Rev	GQ7-Rev	ggtggtggaa caagggcgga gg
13	CisE5	GQ10	ggatccagga ggaccagg
14	CisE5-Rev	GQ10-Rev	ggaccaggag gacctagg
15	CisE6	GQ12	ggcaagagga acaccatctg gctgtttggg
16	CisE6-Rev	GQ12-Rev	gggtttgtcg gtctaccaca aggagaacgg
17	CisE7	GQ14	ggaggaagca aggtgcgcgt gg
18	CisE7-Rev	GQ14-Rev	ggtgcgcgtg gaacgaagga gg
19	CisE8	GQ15	ggtgggcaaa ggatcacgtg gttgaggtgg
20	CisE8-Rev	GQ15-Rev	ggtggagtgt gtgcactagg aaacgggtgg
21	CisE9	GQ16	ggcataagga cgacagcagg gg
22	CisE9-Rev	GQ16-Rev	ggggacgaca gcaggaatac gg
23	CisE10	GQ17	ggggcaacct cggacgagca gtcttccagg
24	CisE10-Rev	GQ17-Rev	ggaccttctg acgagcaggc tccaacgggg
25	CisE11	GQ18	ggttcttgaa cctctgggcc tggttgagg
26	CisE11-Rev	GQ18-Rev	ggagttggtc cgggtctcca agttcttgg
27	CisE12	GQ19	ggctccggga aaaaagaggc cgg
28	CisE12-Rev	GQ19-Rev	ggccggagaa aaaagggcct cgg

SEQ ID NO	Sequence Designation	Source or Origin	Sequence
29	CisE13	GQ20	ggaaccggaa aggcggg
30	CisE13-Rev	GQ20-Rev	gggcggaaag gccaaagg
31	CisE14	GQ22	gggcgccgac ggagtgggta attcctcgg
32	CisE14-Rev	GQ22-Rev	ggctccttaa tgggtgaggc agccgcggg
33	CisE15	GQ23	ggaccagtct aggaactggc ttcctgg
34	CisE15-Rev	GQ23-Rev	ggtccttcgg tcaaggatct gaccagg
35	CisE16	GQ24	ggtgaatccg ggcccggcca tgg
36	CisE16-Rev	GQ24-Rev	ggtaccggcc cgggcctaag tgg
37	CisE17	c-Myc	atggggaggg tggggagggg ggggaagggtg ggga
38	CisE17-Rev	c-Myc-Rev	aggggtggaa ggggtgggag ggggtgggagg ggta
39	CisE18	Chicken β -actin	gggggggggg gggcggg
40	CisE18-Rev	Chicken β -actin-Rev	gggcgggggg ggggggg
41	CisE19	VEGF	ggggcgggcc gggggcgggg tcccggggcg g
42	CisE19-Rev	VEGF-Rev	ggcgggggcc tggggcgggg gccgggcggg g
43	CisE20	BCL-2	aggggcgggc gcgggaggaa gggggcggga gcggggctg
44	CisE20-Rev	BCL-2-Rev	gtcggggcga gggcggggga aggagggcgc gggcgggga

SEQ ID NO	Sequence Designation	Source or Origin	Sequence
45	CisE21	P5	ggtcctgtat tagagggtcac gtgagtgttt tgcgacattt tgcgacacca tgtgggtcacg ctgggtattt aagcccgagt gagcacgcag ggtctccatt ttgaagcggg aggtttgaac ggcgagccgc catgccgggg ttttacgaga ttgtgattaa ggtccccagc gaccttgacg agcatctgcc cggcatttct gacagctttg tgaactgggt ggccgagaag gaatgggagt tgccgccaga ttctgacatg gatctgaatc tgattgagca ggcacccctg accgtggccg agaagctgca gcgcgacttt ctgacggaat ggcgccgtgt gagtaaggcc ccggaggccc ttttctttgt gcaatttgag aaggagaga gctacttcca catgcacgtg ctcgtggaaa ccaccggggt ga
46	CisE21-Rev	P5-Rev	agtggggcca ccaaagggtgc tcgtgcacgt acaccttcat cgagagaggg aagagttaa cgtgtttctt ttcccgagg ccccggaatg agtgtgccgc ggtaaggcag tctttcagcg cgacgtcgaa gagccgggtgc cagtccccac ggacgagtta gtctaagtct aggtacagtc ttagaccgcc gttgagggta aggaagagcc ggtgggtcaa gtgttttcgac agtctttacg gcccgtctac gagcagttcc agcgaccct ggaattagt ttagagcatt ttggggccgt accgccgacg cgcaagtttg gagggcgaag ttttacctct gggacgcacg agtgagccc aatttatggg tcgcactggg gtaccacagc gttttacagc gttttgtgag tgcactggag attatgtcct gg
47	CisE22	P19	gtcacaaaga ccagaaatgg cgccggaggc gggaacaagg tgggtgatga gtgctacatc cccaattact tgctcccaa aaccagcct gagctccagt gggcgtggac taatatggaa cagtatttaa gcgcctgttt gaatctcagc gagcgtaaac ggttgggtggc gcagcatctg
48	CisE22-Rev	P19-Rev	gtctacgacg cgggtggttg caaatgcgag gcaactaag tttgtccgcg aatttatgac aaggtataat cagggtgcggg tgacctcgag tccgaccaa aaccctcgt tcattaaccc ctacatcgtg agtaggtggg ggaacaaggg cggaggccgc ggtaaagacc agaaacactg

SEQ ID NO	Sequence Designation	Source or Origin	Sequence
49	CisE23	P40	gtcacaaaga ccagaaatgg cgccggaggt caccaagcag gaagtcaaag actttttccg gtgggcaaag gatcacgtgg ttgaggtgga gcatgaattc tacgtcaaaa aggggtggagc caagaaaaga cccgccccca gtgacgcaga tataagttag cccaaacggg tgcgcgagtc agttgcgtag ccacgcagct cagacgcggc gggaacaagg tgggtggatga gtgctacatc cccaattact tgctcccca aaccagcct gagctccagt gggcgtggac taatatggaa cagtatttaa gcgcctgttt gaatctcacg gagcgtaaac ggttgggtggc gcagcatctg
50	CisE23-Rev	P40-Rev	gtctacgacg cgggtggttgg caaatgagag gcactctaag tttgtccgag aatttatgac aaggtataat caggtgcggg tgacctcgag tccgacccaa aaccctcgt tcattaaccc ctacatcgtg agtaggtggg ggaacaaggg cggcgcagac tgcagctacc gacgcgttga ctgagcgcgt gggcaaacc gagtgaatat agacgcagtg acccccgccc agaaaagaac cgaggtggga aaaactgcat ctttaagtacg aggtggagtt ggtgcactag gaaacgggtg gcctttttca gaaactgaag gacgaaccac tggaggccgc ggtaaagacc agaaacactg
51	CisE24	P5(209-331)	cgtgagtgtt ttgcgacatt ttgcgacacc atgtggtcac gctgggtatt taagcccgag tgagcacgca ggggtctccat tttgaagcgg gaggtttgaa cgcgcagccg ccatgccggg gtt
52	CisE24-Rev	P5(209-331)-Rev	ttggggccgt accgcccagc cgcaagtattg gagggcgaag ttttacctct gggacgcacg agtgaagccg aatttatggg tcgactggg gtaccacagc gttttacagc gttttgtgag tgc
53	CisE25	P5(317-431)	cgccatgccg gggttttacg agattgtgat taaggtcccc agcgacctt acgagcatct gcccggcatt tctgacagct ttgtgaactg ggtggccgag aaggaatggg agttg

SEQ ID NO	Sequence Designation	Source or Origin	Sequence
54	CisE25-Rev	P5(317-431)-Rev	gttgagggtg aggaagagcc ggtgggtcaa gtgttttcgac agtcttttacg gcccgtctac gagcagttcc agcgaccctt ggaattagtg ttagagcatt ttggggccgt accgc
55	CisE26	P5(406-543)	gggtggccga gaaggaatgg gagttgccgc cagattctga catggatctg aatctgattg agcaggcacc cctgaccgtg gccgagaagc tgcagcgcga ctttctgacg gaatggcgcc gtgtgagtaa ggccccg
56	CisE26-Rev	P5(406-543)-Rev	ggccccggaa tgagtgtgcc gcggttaaggc agtcttttcag cgcgacgtcg aagagccggt gccagtcccc acggacgagt tagtctaagt ctaggtacag tcttagaccg ccgttgaggg taaggaagag ccggtggg
57	CisE27	P143	cgttgaaaac caaattgact ccggtcacta cgttttccaa ttttctaaag aatcctttac acacaatgtc aggcggcaag ttagcgcca tcacattctc gtacgtgtac gccacaatt catcgtgatc caaaatttcg ttttagccg actgagtcaa atatatcatg tagtgtatgc caaaataata gcccaacgat acgcacaatt tggatatcgtc aaagtcaaac caatgattgc aggccctatt aaacactatt ttctcttgtt ttttgtaagg ctacatcgc ttcaaagctt cattcaaagc ttctttgtcg caggcaaata atgattcaca caaaagttcc aaaaacagtt tgatgtcg
58	CisE27-Rev	P143-Rev	gctgtagttt gacaaaaacc ttgaaaacac acttagtaat aaacggacgc tgtttcttcg aaacttactt cgaaacttcg ctacactcgg aatgtttttt gttctctttt atcacaaatt atcccggacg ttagtaacca aactgaaact gctatggttt aacacgcata gcaaccgat aataaaaccg tatgtgatgt actatataaa ctgagtcagc cgatttttgc tttaaacct agtgtactt aacaccgcga tgtgcatgct cttacactac cgcgatttga acggcggact gtaacacaca tttcctaaga aatcttttaa ccttttgcac cactggcctc agttaaacca aaagttgc

SEQ ID NO	Sequence Designation	Source or Origin	Sequence
59	CisE28	CMV	gacattgatt attgactagt tattaatagt aatcaattac ggggtcatta gttcatagcc catatatgga gttccgcgtt acataactta cggtaaatgg cccgcctggc tgaccgcca acgacccccg cccattgacg tcaataatga cgtatgttcc catagtaacg ccaataggga ctttccattg acgtcaatgg gtggagtatt tacggtaaac tgcccacttg gcagtacatc aagtgtatca tatgccaaagt acgcccccta ttgacgtcaa tgacggtaaa tggccgcct ggcattatgc ccagtacatg accttatggg actttcctac ttggcagtac atctacgtat tagtcatcgc tattaccatg gtgatgcggt tttggcagta catcaatggg cgtggatagc ggtttgactc acggggattt ccaagtctcc acccattga cgtcaatggg agtttgttt ggcaccaaaa tcaacgggac tttccaaaat gtcgtataca ctccgccccca ttgacgcaaa tgggcggttag gcgtgtacgg tgggaggtct atataagcag
60	CisE28-Rev	CMV-Rev	gacgaatata tctggagggt ggcatgtgcg gatggcgggt aaacgcagtt acccgcctc aacaatgctg taaaaccttt cagggaact aaaaccacgg ttttgtttga gggtaactgc agttacccca cctctgaacc tttaggggca ctcagtttgg cgatagggtgc gggtaactac atgacggttt tggcgtagtg gtaccattat cgctactgat tatgcatcta catgacggtt catcctttca gggatttcca gtacatgacc cgtattacgg tccgcccggg aaatggcagt aactgcagtt atcccccgca tgaaccgtat actatgtgaa ctacatgacg gttcacccgt caaattggcat ttatgagggt ggtaactgca gttacctttc agggataacc gcaatgatac ccttgatgc agtaataact gcagttaccc gccccagca acccgccagt cggtcgcgcc ggtaaatggc attcaataca ttgcgccttg aggtatatac ccgatacttg attactggg cattaactaa tgataattat tgatcagtta ttagttacag

SEQ ID NO	Sequence Designation	Source or Origin	Sequence
61	CisE29	SV40	gtgtgtcagt taggggtgtgg aaagtcccca ggctccccag caggcagaag tatgcaaagc atgcatctca attagtcagc aaccaggtgt ggaaagtccc caggctcccc agcaggcaga agtatgcaaa gcatgcatct caattagtca gcaaccatag tcccgccccc aactccgccc atcccgcgcc taactccgcc cagtccgccc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg cttttgcaaa
62	CisE29-Rev	SV40-Rev	aaacgttttc ggatccggag gttttttcgg aggagtgatg aagaccttat cgagtctccg gctccgccgg agccggagac gtattttattt tttttaataca gtcgggtacc cgcctcttac ccgccttgac ccgcctcaat ccccgcccta cccgcctcaa tccccgccct gataccaacg actgattaac tctacgtacg aaacgtatga agacggacga cccctcggac ccctgaaagg tgtggaccaa cgactgatta actctacgta cgaaacgtat gaagacggac gaccctcgg acccctgaaa ggtgtgggat tgactgtgtg
63	CisE30	RLTR	gcatcaggcg ccgtgcggta tttcacaccg catatggatc catgcatgtt cgaatttaaa tttaattaac atcatcaata atatacctta ttttggtattg aagccaatat gataatgagg ggggtggagtt tgtgacgtgg cgcgggcggt ggggaacgggg cgggtgacgt aggttttagg gcgagtaaac ttgtatgtgt tgggaattgt agttttctta aaatgggaag tgacgtaacg tgggaatccg gaggcgcccc tgc
64	CisE30-Rev	RLTR-Rev	cgtccccgcg gaggcctaag ggtgcaatgc agtgaagggt aaaattcttt tgatgttaag ggttgtgtat gttcaatgag gcgggatttt ggatgcagtg ggcggggcaa ggggtcgggg cgcggtgcag tgtttgaggt gggggagtaa tagtataacc gaagttaggt tttattccat ataataacta ctacaattaa tttaaattta agcttgtacg tacctaggta tacgccacac tttatggcgt gccgcggact acg

SEQ ID NO	Sequence Designation	Source or Origin	Sequence
65	CisE31	GQ4-7	ggggtggccga gaaggaatgg gagttgccgc cagattctga catggatctg aatctgattg agcaggcacc cctgaccgtg gccgagaagc tgcagcgcga ctttctgacg gaatggcgcc gtgtgagtaa ggccccggag gcccttttct ttgtgcaatt tgagaaggga gagagctact tccacatgca cgtgctcgtg gaaaccaccg gggtgaaatc catgggtttt ggacgtttcc tgagtcagat tcgcgaaaaa ctgattcaga gaatttaccg cgggatcgag ccgactttgc caaactgggt cgcggtcaca aagaccagaa atggcgccgg aggcgggaac aaggtggtgg
66	CisE31-Rev	GQ4-7-Rev	ggtggtggaa caagggcgga ggccgcggta aagaccagaa aactggcgcc ttggtcaaac cgtttcagcc gagctagggc gccatttaag agacttagtc aaaaagcgct tagactgagt cctttgcagg gttttggtac cttaaagtggg gccaccaaa ggtgctcgtg acgtacacct tcatcgagag aggggaagagt ttaacgtggt tcttttccc gaggccccgg aatgagtgtg ccgcggtaag gcagtctttc agcgcgacgt cgaagagccg gtgccagtcc ccacggacga gttagtctaa gtctagggtac agtcttagac cgccgttgag ggtaagggaag agccggtggg
67	CisE32	GQ9-12	ggtcgggtgg ctcgtggaca aggggattac ctcggagaag cagtggatcc aggaggacca ggccctcatac atctccttca atgcggcctc caactcgcg tcccaaatca aggctgcctt ggacaatgcy ggaaagatta tgagcctgac taaaaccgcc cccgactacc tgggtggcca gcagcccgtg gaggacattt ccagcaatcg gatttataaa attttggaaac taaacgggta cgatcccca tatgcggctt ccgtctttct gggatggggc acgaaaaagt tcggcaagag gaacaccatc tggctgtttg gg

SEQ ID NO	Sequence Designation	Source or Origin	Sequence
68	CisE32-Rev	GQ9-12-Rev	gggtttgtcg gtctaccaca aggagaacgg cttgaaaaag caccgggtag ggtctttctg ccttcggcgt ataacccta gcatgggcaa atcaagggtt taaaatat ttt aggctaacga cctttacagg aggtgcccga cgaccgggtg gtccatcagc ccccgccaaa atcagtcgga gtattagaaa gggcgtaaca ggttcgcgtg gaactaaacc ctggcgctca acctccggcg taacttcctc tacatactcc ggaccaggag gacctagggt acgaagaggc tccattaggg gaacagggtg tcggtgggct gg
69	CisE33	GQ14-15	ggaggaagca aggtgcgcggt ggaccagaaa tgcaagtcct cggcccagat agaccgcact cccgtgatcg tcacctcaa caccaacatg tgcgccgtga ttgacgggaa ctcaacgacc ttcgaacacc agcagccgtt gcaagaccgg atgttcaaat ttgaactcac ccgccgtctg gatcatgact ttgggaaggt caccaagcag gaagtcaaag actttttccg gtgggcaaag gatcacgtgg ttgaggtgg
70	CisE33-Rev	GQ14-15-Rev	ggtggagtgt gtgcactagg aaacgggtgg cctttttcag aaactgaagg acgaaccact ggaagggttt cagtactagg tctgccgcc actcaagttt aaacttgtag gccagaacgt tgccgacgac cacaagcttc cagcaactca agggcagtta gtgccgcgtg tacaaccaca acctccactg ctagtgccct cagcccagat agaccgggct cctgaacgta aagaccaggt gcgcgtggaa cgaaggagg

SEQ ID NO	Sequence Designation	Source or Origin	Sequence
71	CisE34	GQ16-22	ggcataagga cgacagcagg ggtcttgtgc ttcctgggta caagtacctc ggacccttca acggactcga caagggagag ccggtcaacg aggcagacgc cgcggccctc gagcacgaca aagcctacga ccggcagctc gacagcggag acaacccgta cctcaagtac aaccacgccg acgcggagtt tcaggagcgc cttaaagaag atacgtcttt tgggggcaac ctcgacgag cagtcttcca ggcgaaaaag agggttcttg aacctctggg cctggttgag gaacctgtta agacggctcc gggaaaaaag aggccggtag agcactctcc tgtggagcca gactcctcct cgggaaccgg aaaggcgggc cagcagcctg caagaaaaag attgaatttt ggtcagactg gagacgcaga ctacgtacct gacccccagc ctctcggaca gccaccagca gccccctctg gtctgggaac taatacgatg gctacaggca gtggcgcacc aatggcagac aataacgagg gcgccgacgg agtgggtaat tcctcgg
72	CisE34-Rev	GQ16-22-Rev	ggctccttaa tgggtgaggc agccgcggga gcaataacag acggtaacca cgcggtgacg gacatcggta gcataatcaa gggctctggc tcccccgacg accaccgaca ggctctccga ccccagtcct atgactcaga cgcagaggtc agactggttt taagttagaa aaagaacgtc cgacgaccgg gcggaaaggc caagggtcct tcctcagacc gaggtgtcct ctcacgagat ggcccgagaa aaaagggcct cggcagaatt gtccaaggag ttggtccggg tctccaagtt cttgggagaa aaagcggacc ttctgacgag caggctccaa cgggggtttt ctgcatagaa gaaattccgc gaggactttg aggcgcagcc gcaccaacat gaactccatg cccaacagag gcgacagctc gacggccagc atccgaaaca gcacgagctc ccggcgccgc agacggagca actggccgag agggaacagc tcaggcaact tcccaggctc catgaacatg ggtccttcgt gttctgggga cgacagcagg aatacgg

SEQ ID NO	Sequence Designation	Source or Origin	Sequence
73	CisE35	GQ23-25	ggaccagtct aggaactggc ttcttgacc ctgttaccgc cagcagcgag tatcaaagac atctgcggat aacaacaaca gtgaatactc gtggactgga gctaccaagt accacctcaa tggcagagac tctctggtga atccgggccc ggccatggca agccacaagg acgatgaaga aaagtttttt cctcagagcg gggttctcat ctttgggaag caagg
74	CisE35-Rev	GQ23-25-Rev	ggaacgaagg gtttctactc ttggggcgag actccttttt tgaaaagaag tagcaggaaac accgaacggt accggcccgg gcctaagtgg tctctcagag acggtaactc caccatgaac catcgaggtc aggtgctcat aagtgacaac aacaataggc gtctacagaa actatgagcg acgaccgcca ttgtcccagg tccttcggtc aaggatctga ccagg

[0081] The inclusion of one or more of the Cis-Elements of the present invention increases rAAV production titers. As used herein, the term “**production titer**” is intended to denote the amount of concentration of infectious rAAV in a preparation. Such amounts or concentrations are preferably determined by titrating the AAV or rAAV in such preparation. The production titers of the rAAV preparations of the present invention are preferably titrated after subjecting producing cells (*e.g.*, HEK293 transformed with an rAAV plasmid vector, an AAV helper vector providing **Rep** and **Cap** proteins, and an Ad helper vector providing required adenovirus transcription and translation factors) to three rounds of freeze / thawing, followed by sonication to release the rAAV particles. The preparation is then centrifuged. The employed AAV helper vector is localized to the supernatant. An aliquot of the preparation is treated with proteinase K, and the number of AAV genomes is determined. An aliquot of the preparation is infected into HeLa-32C2 cells (which express AAV2 **Rep** and **Cap** proteins, and infectious titer is measured using the infectious center assay (**ICA**) (François, A. *et al.* (2018) “*Accurate Titration of Infectious AAV Particles Requires Measurement of Biologically Active Vector Genomes and Suitable Controls*,” Molec. Ther. Meth. Clin. Develop. 10:223-236) or more preferably, as the median tissue culture infective dose (**TCID₅₀**) (Zen, Z. *et al.* (2004) “*Infectious Titer Assay For Adeno-*

Associated Virus Vectors With Sensitivity Sufficient To Detect Single Infectious Events,” Hum. Gene Ther. 15:709-715).

[0082] As used herein, an rAAV production titer is said to be “**increased**” by the methods of the present invention if the production titer obtained from the use of the methods of the present invention is at least 10% greater, more preferably at least 20% greater, still more preferably at least 30% greater, still more preferably at least 40% greater, still more preferably at least 50% greater, still more preferably at least 60% greater, still more preferably at least 70% greater, still more preferably at least 80% greater, still more preferably at least 90% greater, still more preferably at least 2-fold greater, still more preferably at least 110% greater, still more preferably at least 120% greater, still more preferably at least 130% greater, still more preferably at least 140% greater, still more preferably at least 2.5-fold greater, still more preferably at least 160% greater, still more preferably at least 170% greater, still more preferably at least 180% greater, still more preferably at least 190% greater, and still more preferably at least 3-fold greater than the titer obtained from a similarly conducted production in which the additionally provided ions were not provided.

[0083] The rAAV whose production titer may be increased using the methods of the present invention may comprise any transgene cassette that permits the rAAV to be packaged into an rAAV plasmid vector that may be encapsidated within an AAV capsid particle. Without limitation, such transgene cassette(s) may be of human, primate (including chimpanzee, gibbon, gorilla, orangutan, *etc.*), cercopithecine (including baboon, cynomolgus monkey, velvet monkey, *etc.*), canine, glirine (including rat, mouse, hamster, guinea pig, *etc.*), feline, ovine, caprine, or equine origin.

[0084] In preferred embodiments, such an rAAV or rAAV plasmid vector will encode a protein (*e.g.*, an enzyme, hormone, antibody, receptor, ligand, *etc.*), or comprise a transcribed nucleic acid, that is relevant to a genetic or heritable disease or condition, such that it may be used in gene therapy to treat such disease or condition.

[0085] The methods of the present invention may be used to increase the production titer of rAAV and rAAV plasmid vectors in cells that have been transfected with a desired rAAV or rAAV plasmid vector, and with such one or more viruses and/or helper plasmids that can provide proteins or RNA molecules that are not provided by such

rAAV or rAAV plasmid vectors, but are required for their production. As discussed above, such proteins or RNA molecules include the genes encoding the **Rep52** and **Rep78** proteins that are required for vector transcription control and replication, and for the packaging of viral genomes into the viral capsule, and, in the case of rAAV, *cap* genes that encode VP capsid proteins required to form infectious particles. Such proteins or RNA molecules also include the viral transcription and translation factors (E1a, E1b, E2a, VA and E4) required for AAV proliferation. In one embodiment for producing the rAAV of the present invention, all of these genes and RNA molecules are provided on the same helper virus (or more preferably, helper vector) so as to comprise, in concert with an rAAV, a double plasmid transfection system. More preferably, however, for producing the rAAV of the present invention, the required *rep* and *cap* genes are provided by one plasmid, and the genes that encode the viral transcription and translation factors are provided on a second plasmid, so that such plasmids, in concert with the rAAV, comprise a triple plasmid transfection system.

[0086] The methods of the present invention may be employed to increase the production titer of rAAV belonging to any serotype, including the AAV1, AAV2, AAV5, AAV6, AAV7, AAV8, AAV9 and AAV10 serotypes and the rAAV1, rAAV2, rAAV5, rAAV6, rAAV7, rAAV8, rAAV9, and rAAV10 serotypes, and including hybrid serotypes (*e.g.*, AAV2/5 and rAAV2/5, which is a hybrid of serotypes 2 and 5 and thus has the tropism of both such serotypes).

[0087] The methods of the present invention may be employed to increase the production titers of rAAV that are to be produced using “helper” RNA or proteins provided by an adenovirus, a herpes simplex virus, a cytomegalovirus, a vaccinia virus or a papillomavirus.

[0088] The methods of the present invention may be employed to increase the production titers of rAAV produced by cells in adherent monolayer culture or in suspension culture, and may be used with any method capable of producing rAAV. Preferably, however, rAAV is produced by transfecting baby hamster kidney (BHK) cells, or more preferably, human embryonic kidney (HEK) cells grown in tissue culture with the plasmid vectors described above. The BHK cell line BHK-21 (ATCC CCL-10), which lacks endogenous retroviruses is a preferred BHK cell line. The HEK cell

line HEK293 (ATCC CRL-1573) and its derivatives, such as HEK293T (ATCC CRL-3216, which is a highly transfectable derivative of the HEK293 cell line into which the temperature-sensitive gene for SV40 T-antigen was inserted) or HEK293T/17 (ATCC® CRL-11268, which was selected for its ease of transfection) are particularly preferred. The HEK293T/17 SF cell line (ATCC ACS-4500) is a derivative of the 293T/17 cell line (ATCC CRL-11268), adapted to serum-free medium and suspension, and may be employed if desired.

[0089] The preferred base medium of the present invention for culturing such cells is Eagle's Minimum Essential Medium (ATCC Catalog No. 30-2003) or Dulbecco's Modified Eagle's Medium (DMEM; Mediatech, Manassas, VA). Fetal bovine serum (*e.g.*, FBS; HyClone Laboratories, South Logan, UT) is added to a final concentration of 10% in order to make the complete growth medium. Eagle's Minimum Essential Medium and Dulbecco's Modified Eagle's Medium are complex media that contain amino acids, vitamins, and optionally glucose, in addition to various inorganic salts. The media differ in that Dulbecco's modified Eagle's medium contains approximately four times as much of the vitamins and amino acids present in the original formula of Eagle's Minimum Essential Medium, and two to four times as much glucose. Additionally, it contains iron in the form of ferric sulfate and phenol red for pH indication (Yao, T *et al.* (2017) "*Animal-Cell Culture Media: History, Characteristics, And Current Issues*," *Reproduc. Med. Biol.* 16(2): 99-117).

[0090] Cells to be used for such transfection are preferably passaged twice weekly to maintain them in exponential growth phase. For small-scale transfections, an aliquot of, for example, 1×10^6 HEK293 or BHK cells per well on a multi-well plate, or 1.5×10^7 HEK293 cells per 15-cm dish, may be employed. For large-scale production HEK293 or BHK cells may be collected from multiple confluent 15-cm plates, and split into two 10-layer cell stacks (Corning, Corning, NY) containing 1 liter of complete culturing medium. In one embodiment, such cells are grown for 4 days in such medium before transfection. The day before transfection, the two cell stacks may be trypsinized and the cells (*e.g.*, approximately 6×10^8 cells) may be resuspended in 200 ml of medium. Preferably, the cells are allowed to attach for 24 hours before transfection. Confluency of the cell stacks may be monitored using a Diaphot inverted microscope

(Nikon, Melville, NY) from which the phase-contrast hardware had been removed in order to accommodate the cell stack on the microscope stage.

[0091] In particular, the present invention thus provides a method for increasing the production titer of a recombinantly-modified AAV (rAAV) wherein such method comprises the steps:

- (A) employing, as the rAAV for producing the production titer, an rAAV that has been modified to comprise an added Cis-Element in one or more of its **P1**, **P2**, **P3** or **P4 Domains**, wherein:
 - (1) the **P1 Domain** is 5' to a 5' ITR of the rAAV;
 - (2) the **P2 Domain** is 3' to the 5' ITR of the rAAV and 5' to a transgene cassette of the rAAV;
 - (3) the **P3 Domain** is 3' to the transgene cassette of the rAAV and 5' to a 3' ITR of the rAAV; and
 - (4) the **P4 Domain** is 3' to the 3' ITR of the rAAV; and
- (B) culturing cells that have been transfected with the employed rAAV, wherein the cells additionally contain an AAV helper function-providing polynucleotide and a non-AAV helper function-providing polynucleotide, and wherein the culturing is conducted in a culture medium under conditions sufficient to permit the production of rAAV;

wherein the presence of the Cis-Element in the employed rAAV causes the cells to produce the rAAV at an increased production titer relative to that which would be attained if the employed rAAV had lacked the Cis-Element.

II. Pharmaceutical Compositions of the Present Invention

[0092] The present invention provides a pharmaceutical composition that comprises:

- (A) a preparation of recombinantly-modified adeno-associated virus (rAAV) that comprise a Cis-Element in one or more of its **P1**, **P2**, **P3** or **P4 Domains**, wherein:
 - (1) the **P1 Domain** is 5' to a 5' ITR of the rAAV;
 - (2) the **P2 Domain** is 3' to the 5' ITR of the rAAV and 5' to a transgene cassette of the rAAV;

- (3) the **P3 Domain** is 3' to the transgene cassette of the rAAV and 5' to a 3' ITR of the rAAV; and
- (4) the **P4 Domain** is 3' to the 3' ITR of the rAAV; and
- (B) a pharmaceutically acceptable carrier.

[0093] The invention additionally includes pharmaceutical compositions that comprise a pharmaceutically acceptable preparation of rAAV produced in accordance with the methods of the present invention, and a pharmaceutically acceptable carrier. The rAAV of such pharmaceutical compositions comprises a transgene cassette that encodes a protein, or comprises a transcribed nucleic acid, that is therapeutic for a genetic or heritable disease or condition, and is present in such pharmaceutical composition in an amount effective to ("**effective amount**")

[0094] The term "**pharmaceutically acceptable**" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "**carrier**" refers to a diluent, adjuvant (*e.g.*, Freund's adjuvant (complete and incomplete), excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. Suitable pharmaceutical excipients are described in US Patents No. 8,852,607; 8,192,975; 6,764,845; 6,759,050; and 7,598,070.

[0095] Generally, the ingredients of compositions of the invention are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate, or as an aqueous solution in a hermetically sealed container such as a vial, an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline, or other diluent can be provided so that the ingredients may be mixed prior to administration.

[0096] The invention also provides a pharmaceutical pack or kit comprising one or more containers such pharmaceutical composition. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

[0097] The rAAV of such pharmaceutical compositions is preferably packaged in a hermetically sealed container, such as a vial, an ampoule or sachette indicating the quantity of the molecule, and optionally including instructions for use. In one embodiment, the rAAV of such kit is supplied as a dry sterilized lyophilized powder or water-free concentrate in a hermetically sealed container and can be reconstituted, *e.g.*, with water, saline, or other diluent to the appropriate concentration for administration to a subject. The lyophilized material should be stored at between 2°C and 8°C in their original container and the material should be administered within 12 hours, preferably within 6 hours, within 5 hours, within 3 hours, or within 1 hour after being reconstituted. In another embodiment, the rAAV of such kit is supplied as an aqueous solution in a hermetically sealed container and can be diluted, *e.g.*, with water, saline, or other diluent, to the appropriate concentration for administration to a subject. The kit can further comprise one or more other prophylactic and/or therapeutic agents useful for the treatment of the disease or condition, in one or more containers; and/or the kit can further comprise one or more cytotoxic antibodies that bind one or more cancer antigens associated with cancer. In certain embodiments, the other prophylactic or therapeutic agent is a chemotherapeutic. In other embodiments, the prophylactic or therapeutic agent is a biological or hormonal therapeutic.

III. Uses of the Invention

[0098] The methods of the present invention may be used to facilitate the production of rAAV, and may particularly be used to facilitate the production of rAAV that comprise transgene cassettes that encode a protein (*e.g.*, an enzyme, hormone, antibody, receptor, ligand, *etc.*), or of rAAV that comprise a transcribed nucleic acid, that is relevant to a genetic or heritable disease or condition, such that it may be used in gene therapy to treat such disease or condition. Examples of such diseases and conditions include: achromatopsia (**ACHM**); alpha-1 antitrypsin (**AAT**) deficiency; Alzheimer's Disease; aromatic L-amino acid decarboxylase (**AADC**) deficiency; choroideremia (**CHM**); cancer; Duchenne muscular dystrophy; dysferlin deficiency; follistatin gene deficiency (**BMD5IBM**); hemophilia A; hemophilia B; hepatitis A; hepatitis B; hepatitis C; Huntington's disease; idiopathic Parkinson's disease; late-infantile neuronal ceroid lipofuscinosis (**LINCL**, an infantile form of Batten disease); Leber congenital amaurosis (**LCA**); Leber's hereditary optic neuropathy (**LHON**); limb girdle muscular dystrophy 1B (**LGMD1B**); limb girdle muscular dystrophy 1C (**LGMD1C**); limb girdle muscular dystrophy 2A (**LGMD2A**); limb girdle muscular dystrophy 2B (**LGMD2B**); limb girdle muscular dystrophy 2I (**LGMD2I**); limb girdle muscular dystrophy 2L (**LGMD2L**); lipoprotein lipase (**LPL**) deficiency; metachromatic leukodystrophy; neurological disability; neuromotor deficit; neuroskeletal impairment; Parkinson's disease; rheumatoid arthritis; Sanfilippo A syndrome; spinal muscular atrophy (**SMA**); X-linked retinoschisis (**XLRS**); α -sarcoglycan deficiency (**LGMD2D**); β -sarcoglycan deficiency (**LGMD2E**); γ -sarcoglycan deficiency (**LGMD2C**) and δ -sarcoglycan deficiency (**LGMD2F**).

IV. Embodiments of the Invention

[0099] The invention concerns a recombinantly-modified adeno-associated virus (AAV) helper vector that comprises an AAV helper function-providing polynucleotide, and uses and compositions thereof. It is particularly directed to the following embodiments **E1-E22**:

E1. A recombinantly-modified adeno-associated virus (rAAV) that comprises a Cis-Element in one or more of its **P1**, **P2**, **P3** or **P4 Domains**, wherein:

- (1) the **P1 Domain** is 5' to a 5' ITR of the rAAV;

- (2) the **P2 Domain** is 3' to the 5' ITR of the rAAV and 5' to a transgene cassette of the rAAV;
- (3) the **P3 Domain** is 3' to the transgene cassette of the rAAV and 5' to a 3' ITR of the rAAV; and
- (4) the **P4 Domain** is 3' to the 3' ITR of the rAAV; and

wherein the presence of the Cis-Element causes rAAV-producing cells to produce the rAAV at a higher production titer than would be attained with such rAAV if lacking the Cis-Element.

E2. A pharmaceutical composition that comprises:

- (A) a preparation of recombinantly-modified adeno-associated virus (rAAV) that comprise a Cis-Element in one or more of its **P1, P2, P3** or **P4 Domains**, wherein:
 - (1) the **P1 Domain** is 5' to a 5' ITR of the rAAV;
 - (2) the **P2 Domain** is 3' to the 5' ITR of the rAAV and 5' to a transgene cassette of the rAAV;
 - (3) the **P3 Domain** is 3' to the transgene cassette of the rAAV and 5' to a 3' ITR of the rAAV; and
 - (4) the **P4 Domain** is 3' to the 3' ITR of the rAAV; and
- (B) a pharmaceutically acceptable carrier.

E3. A method for increasing the production titer of recombinantly-modified adeno-associated virus (rAAV), wherein the method comprises:

- (A) employing, as the rAAV for producing the production titer, an rAAV that has been modified to comprise an added Cis-Element in one or more of its **P1, P2, P3** or **P4 Domains**, wherein:
 - (1) the **P1 Domain** is 5' to a 5' ITR of the rAAV;
 - (2) the **P2 Domain** is 3' to the 5' ITR of the rAAV and 5' to a transgene cassette of the rAAV;
 - (3) the **P3 Domain** is 3' to the transgene cassette of the rAAV and 5' to a 3' ITR of the rAAV; and
 - (4) the **P4 Domain** is 3' to the 3' ITR of the rAAV; and
- (B) culturing cells that have been transfected with the employed rAAV, wherein the cells additionally contain an AAV helper function-providing polynucleotide and a non-AAV helper function-providing

polynucleotide, and wherein the culturing is conducted in a culture medium under conditions sufficient to permit the production of rAAV; wherein the presence of the Cis-Element in the employed rAAV causes the cells to produce the rAAV at an increased production titer relative to that which would be attained if the employed rAAV had lacked the Cis-Element.

- E4.** The recombinantly-modified adeno-associated virus (rAAV) of **E1**, the pharmaceutical composition of **E2**, or the method of **E3**, wherein the employed rAAV has been modified to comprise an added Cis-Element in its **P1 Domain**.
- E5.** The recombinantly-modified adeno-associated virus (rAAV) of **E1**, the pharmaceutical composition of **E2**, or the method of **E3**, wherein the employed rAAV has been modified to comprise an added Cis-Element in its **P2 Domain**.
- E6.** The recombinantly-modified adeno-associated virus (rAAV) of **E1**, the pharmaceutical composition of **E2**, or the method of **E3**, wherein the employed rAAV has been modified to comprise an added Cis-Element in its **P3 Domain**.
- E7.** The recombinantly-modified adeno-associated virus (rAAV) of **E1**, the pharmaceutical composition of **E2**, or the method of **E3**, wherein the employed rAAV has been modified to comprise an added Cis-Element in its **P4 Domain**.
- E8.** The recombinantly-modified adeno-associated virus (rAAV) of **E1**, the pharmaceutical composition of **E2**, or the method of **E3**, wherein the employed rAAV has been modified to comprise an added Cis-Element in its **P1 Domain** and in one or more of its **P2**, **P3** or **P4 Domain**.
- E9.** The recombinantly-modified adeno-associated virus (rAAV) of **E1**, the pharmaceutical composition of **E2**, or the method of **E3**, wherein the employed rAAV has been modified to comprise an added Cis-Element in its **P2 Domain** and in one or more of its **P3** or **P4 Domain**.
- E10.** The recombinantly-modified adeno-associated virus (rAAV) of **E1**, the pharmaceutical composition of **E2**, or the method of **E3**, wherein the employed rAAV has been modified to comprise an added Cis-Element in its **P3 Domain** and in its **P4 Domain**.
- E11.** The recombinantly-modified adeno-associated virus (rAAV) of any one of **E1** or **E4-E10**, the pharmaceutical composition of any one of **E2** or **E4-E10**, or the

method of any one of **E3-E10**, wherein the added Cis-Element forms a G-Quadruplex Structure in the employed rAAV.

E12. The recombinantly-modified adeno-associated virus (rAAV) of any one of **E1** or **E4-E11**, the pharmaceutical composition of any one of **E2** or **E4-E11**, or the method of any one of **E3-E11**, wherein an added Cis-Element is selected from the group consisting of:

- (1) a Potential G-Quadruplex Sequence of a wild type AAV genome or a Potential G-Quadruplex Sequence of a wild type AAV genome in a reversed orientation;
- (2) an Actual G-Quadruplex Sequence of a wild type AAV genome or an Actual G-Quadruplex Sequence of a wild type AAV genome in a reversed orientation;
- (3) a DNA sequence from wild-type AAV or a DNA sequence from wild-type AAV in a reversed orientation; and
- (4) a DNA sequence from another viral genome or a DNA sequence from another viral genome in a reversed orientation.

E13. The recombinantly-modified adeno-associated virus (rAAV) of any one of **E1** or **E4-E12**, the pharmaceutical composition of any one of **E2** or **E4-E12**, or the method of any one of **E3-E12**, wherein the transgene cassette encodes a protein, or comprises a transcribed nucleic acid, that is therapeutic for a genetic or heritable disease or condition.

E14. The recombinantly-modified adeno-associated virus (rAAV) of any one of **E1** or **E4-E13**, the pharmaceutical composition of any one of **E2** or **E4-E13**, or the method of any one of **E3-E13**, wherein the employed rAAV belongs to the rAAV1, rAAV2, rAAV5, rAAV6, rAAV7, rAAV8, rAAV9 or rAAV10 serotype, or to a hybrid of the serotypes.

E15. The recombinantly-modified adeno-associated virus, the pharmaceutical composition, or the method of **E14**, wherein the employed rAAV belongs to the rAAV2, rAAV5, or rAAV9 serotype, or to a hybrid of the serotypes.

E16. The recombinantly-modified adeno-associated virus (rAAV) of any one of **E1** or **E4-E15**, or the method of any one of **E3-E15**, wherein the cells are human embryonic kidney cells.

- E17.** The recombinantly-modified adeno-associated virus (rAAV) of **E16**, or the method of **E16**, wherein the cells are human embryonic kidney cells.
- E18.** The recombinantly-modified adeno-associated virus (rAAV) of **E17**, or the method of **E17**, wherein the are HEK293 cells.
- E19.** The recombinantly-modified adeno-associated virus (rAAV) of **E16**, or the method of **E16**, wherein the cells are baby hamster kidney cells.
- E20.** The recombinantly-modified adeno-associated virus (rAAV) of **E19**, or the method of **E19**, wherein the are BHK21 cells.
- E21.** The recombinantly-modified adeno-associated virus (rAAV) of **E16**, or the method of **E16**, wherein the cells are sf9 insect cells.
- E22.** The preparation of recombinantly-modified adeno-associated virus (rAAV) of **E14**, or the pharmaceutical composition of **E15**, wherein the transgene cassette encodes a protein, or comprises a transcribed nucleic acid, that is therapeutic for a genetic or heritable disease or condition, for use in the treatment of the genetic or heritable disease or condition.

EXAMPLES

[00100] Having now generally described the invention, the same will be more readily understood through reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention unless specified.

Example 1

Comparison of rAAV Production Titers by Cells Transfected with rAAV Plasmid Vectors Having a Cis-Element within the rAAV Plasmid Vector's P2 Domain

[00101] In order to demonstrate the ability of the Cis-Elements of the present invention to increase rAAV production titers, the parent rAAV plasmid vector **pAV-TBG-EGFP** was modified to contain a cis element within its **P2 Domain**.

[00102] A series of 27 derivatives of plasmid **pAV-TBG-EGFP** were constructed by inserting one of Cis-Element CisE1-CisE27 (**Table 1**) into the **SpeI** site of the plasmid that is located within the plasmid's **P2 Domain** (**Figure 7**; **Figure 9A**). The production titers of rAAV obtained using the derivative plasmids in a triple plasmid transfection system (**Figure 2**) with the AAV helper plasmid **pRC2** providing the AAV *rep* and *cap*

functions and the Ad helper plasmid **pHelper** that provided the required adenoviral functions were measured and compared to those obtained with the parental **pAV-TBG-EGFP** plasmid.

[00103] The results of the investigation are shown in **Figure 9B**, and indicate that all of the Cis-Elements introduced within the **P2 Domain** of the rAAV plasmid vector **pAV-TBG-EGFP** resulted in an increase in rAAV production titer. The insertion of CisE19 into the **P2 Domain** of the rAAV plasmid vector was found to mediate a 2.5-fold increase in production titer. The insertion of CisE26 into the **P2 Domain** of the rAAV plasmid vector was found to mediate a 4-fold increase in production titer.

Example 2

Comparison of rAAV Production Titers by Cells Transfected with rAAV Plasmid Vectors Having a Cis-Element within the rAAV Plasmid Vector's P1 Domain

[00104] In order to further demonstrate the ability of the Cis-Elements of the present invention to increase rAAV production titers, the rAAV plasmid vector, **pAV-TBG-EGFP** was modified to contain a Cis-Element within the plasmid's **P1 Domain**. The effect of that modification on rAAV titer was then assessed as described above.

[00105] More specifically, a series of 7 derivatives of rAAV plasmid vector **pAV-TBG-EGFP** were constructed by inserting one of Cis-Element CisE1, CisE20, CisE21, CisE27, CisE28, CisE29, or CisE30 (**Table 1**) into the **PciI** site of the plasmid that is located within the plasmid's **P1 Domain** (**Figure 7**; **Figure 10A**). The production titers of rAAV were obtained essentially as described in **Example 1** using a triple plasmid transfection system (**Figure 2**) with an AAV helper plasmid providing the AAV *rep* and *cap* functions (**pHelper-Kan**) and an Ad helper plasmid that provided the required adenoviral functions (**pRC2**). The production titers were compared with those obtained with the parental **pAV-TBG-EGFP** plasmid. The results of the investigation are shown in **Figure 10B**, and indicate that all of the Cis-Elements introduced within the **P1 Domain** of **pAV-TBG-EGFP** resulted in an increase in rAAV production titer. The insertion of CisE30 within the **P1 Domain** of the rAAV plasmid vector was found to mediate a 3.0-fold increase in production titer.

Example 3

Comparison of rAAV Production Titers by Cells Transfected with rAAV Plasmid Vectors Having a Cis-Element within Either the rAAV Plasmid Vector's P1 Domain or P2 Domain

[00106] The effect on rAAV production titers of inserting the same Cis-Element either within the **P1 Domain** of an rAAV plasmid vector or within the **P2 Domain** of such rAAV plasmid vector was investigated by introducing Cis-Element CisE1, CisE20 or CisE21 into either the **P1 Domain** of the rAAV plasmid vector **pAV-TBG-EGFP** or within the **P2 Domain** of plasmid vector **pAV-TBG-EGFP** (**Figure 11A**), essentially as described above.

[00107] The production titers of rAAV were obtained essentially as described in **Example 1** using a triple plasmid transfection system (**Figure 2**) with an AAV helper plasmid providing the AAV *rep* and *cap* functions (**pHelper**) and an Ad helper plasmid that provided the required adenoviral functions (**pRC2**). The results of the investigation are shown in **Figure 11B**, and indicate that positioning a Cis-Element within either the **P1** or **P2 Domain** of an rAAV plasmid vector resulted in an increase in rAAV production titer.

Example 4

Effect of Orientation of Cis-Elements in an rAAV Plasmid Vector on rAAV Yield Produced by Transfected Cells

[00108] The effect of the orientation of a Cis-Element in an rAAV plasmid vector on rAAV production titers was investigated by inserting the Cis-Element CisE21 (**Table 1**) within the **P1 Domain** of the rAAV plasmid vector **pAV-TBG-EGFP** in either the “forward” orientation (**SEQ ID NO:45**) or in the “reverse” orientation (**SEQ ID NO:46**) (**Figure 12A**), essentially as described above.

[00109] The production titers of rAAV were obtained essentially as described in **Example 1** using a triple plasmid transfection system (**Figure 2**) with an AAV helper plasmid (**pRC2**) providing the AAV *rep* and *cap* functions and an Ad helper plasmid (**pHelper**) that provided the required adenoviral functions. The results of the investigation are shown in **Figure 12B**, and indicate that an increased rAAV production titer was obtained using rAAV plasmid vectors having either orientation of the inserted Cis-Element.

Example 5

Comparison of rAAV Production Titers by Cells Transfected with rAAV Plasmid Vectors Having a Cis-Element within the rAAV Plasmid Vector's P1 Domain and Its P4 Domain

[00110] The effect on rAAV production titers of inserting different Cis-Elements within the **P1 Domain** of an rAAV plasmid vector, while maintaining the same Cis-Element within the **P4 Domain** of such rAAV plasmid vector (**Figure 13A**), was investigated by introducing different Cis-Elements within the **P1 Domain** of an rAAV plasmid vector that contained the same Cis-Element in the **KasI** site that is located within the **P4 Domain** of such rAAV plasmid vector. The production titers of rAAV were obtained essentially as described in **Example 1** using a triple plasmid transfection system (**Figure 2**) with an AAV helper plasmid providing the AAV *rep* and *cap* functions and an Ad helper plasmid that provided the required adenoviral functions.

[00111] The results of the investigation are shown in **Figure 13B** and **Figure 13C**. **Figure 13B** shows the production titers of rAAV that were obtained using plasmid vector **pAV-TBG-EGFP** that contained Cis-Element CisE21, CisE22, CisE23, CisE24, CisE25, CisE26, CisE28, CisE29, CisE31, CisE32, CisE33, CisE34, or CisE35 within its **P1 Domain** and Cis-Element CisE30-Rev within its **P4 Domain**. **Figure 13C** shows the production titers of rAAV that were obtained using plasmid vector **pAV-TBG-EGFP** that contained Cis-Element CisE21, CisE22, CisE23, CisE24, CisE25, CisE27, CisE28, CisE32, CisE33, or CisE34 within its **P1 Domain** and Cis-Element CisE35-Rev within its **P4 Domain**. The results of the investigation indicate that the presence of two Cis-Elements in the rAAV plasmid vectors synergistically enhanced the increased production titer, relative to that obtained using only a single Cis-Element.

[00112] The effect on rAAV production titers of inserting different Cis-Elements within the **P4 Domain** of an rAAV plasmid vector, while maintaining the same Cis-Element within the **P1 Domain** of such rAAV plasmid vector, was investigated by introducing Cis-Element CisE28 into the **P1 Domain** of the rAAV plasmid vector **pAV-TBG-EGFP**. The plasmid vectors were then further modified to contain Cis-Element CisE22-Rev, CisE27-Rev, CisE29-Rev, or CisE35-Rev within its **P4 Domain** (**Figure 13D**), essentially as described above. An rAAV having a Cis28 Cis-Element

within its **P1 Domain** and a CisE35-Rev Cis-Element within its **P4 Domain** exhibited a 2-3 fold increased production titer relative to that of the parent rAAV.

[00113] All publications and patents mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference in its entirety. While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth.